<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533612467824</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533612467824</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug–Vitamin D Interactions</article-title>
<subtitle>A Systematic Review of the Literature</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Robien</surname><given-names>Kim</given-names></name>
<degrees>PhD, RD, CSO</degrees>
<xref ref-type="aff" rid="aff1-0884533612467824">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oppeneer</surname><given-names>Sarah J.</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-0884533612467824">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kelly</surname><given-names>Julia A.</given-names></name>
<degrees>MS, MLIS</degrees>
<xref ref-type="aff" rid="aff3-0884533612467824">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hamilton-Reeves</surname><given-names>Jill M.</given-names></name>
<degrees>PhD, RD</degrees>
<xref ref-type="aff" rid="aff4-0884533612467824">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533612467824"><label>1</label>Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, DC</aff>
<aff id="aff2-0884533612467824"><label>2</label>Division of Epidemiology and Community Health, University of Minnesota, Minneapolis</aff>
<aff id="aff3-0884533612467824"><label>3</label>University Libraries, University of Minnesota, Minneapolis</aff>
<aff id="aff4-0884533612467824"><label>4</label>University of Kansas Medical Center, School of Health Professions, Department of Dietetics &amp; Nutrition, Kansas City, Kansas</aff>
<author-notes>
<corresp id="corresp1-0884533612467824">Kim Robien, PhD, RD, CSO, Associate Professor, Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, 2100-W Pennsylvania Ave NW, 8th Floor, Washington, DC, 20037, USA. Email: <email>krobien@gwu.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<issue-title>Research and Publishing</issue-title>
<fpage>194</fpage>
<lpage>208</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Extensive media coverage of the potential health benefits of vitamin D supplementation has translated into substantial increases in supplement sales over recent years. Yet, the potential for drug–vitamin D interactions is rarely considered. This systematic review of the literature was conducted to evaluate the extent to which drugs affect vitamin D status or supplementation alters drug effectiveness or toxicity in humans. Electronic databases were used to identify eligible peer-reviewed studies published through September 1, 2010. Study characteristics and findings were abstracted, and quality was assessed for each study. A total of 109 unique reports met the inclusion criteria. The majority of eligible studies were classified as class C (nonrandomized trials, case-control studies, or time series) or D (cross-sectional, trend, case report/series, or before-and-after studies). Only 2 class C and 3 class D studies were of positive quality. Insufficient evidence was available to determine whether lipase inhibitors, antimicrobial agents, antiepileptic drugs, highly active antiretroviral agents, or H<sub>2</sub> receptor antagonists alter serum 25(OH)D concentrations. Atorvastatin appears to increase 25(OH)D concentrations, whereas concurrent vitamin D supplementation decreases concentrations of atorvastatin. Use of thiazide diuretics in combination with calcium and vitamin D supplements may cause hypercalcemia in the elderly or those with compromised renal function or hyperparathyroidism. Larger studies with stronger study designs are needed to clarify potential drug–vitamin D interactions, especially for drugs metabolized by cytochrome P450 3A4 (CYP3A4). Healthcare providers should be aware of the potential for drug–vitamin D interactions.</p>
</abstract>
<kwd-group>
<kwd>vitamin D</kwd>
<kwd>drug interactions</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Vitamin D, a steroid hormone precursor, is well known for its role in maintaining calcium homeostasis and normal bone structure. Recent evidence suggests that the vitamin may also play a role in a variety of other physiologic processes such as modulation of inflammatory pathways<sup><xref ref-type="bibr" rid="bibr1-0884533612467824">1</xref></sup> and susceptibility to diabetes,<sup><xref ref-type="bibr" rid="bibr2-0884533612467824">2</xref></sup> cancer,<sup><xref ref-type="bibr" rid="bibr3-0884533612467824">3</xref></sup> and infectious<sup><xref ref-type="bibr" rid="bibr4-0884533612467824">4</xref></sup> and cardiovascular<sup><xref ref-type="bibr" rid="bibr5-0884533612467824">5</xref></sup> diseases. Extensive media coverage of the potential health benefits of vitamin D has translated into vitamin D supplement sales in the United States increasing from $75 million in 2006 to $550 million in 2010.<sup><xref ref-type="bibr" rid="bibr6-0884533612467824">6</xref></sup> Supplemental vitamin D is available in doses that can be considered pharmacologic (&gt;600 IU) compared with the usual US dietary intake (approximately 160–200 IU/d<sup><xref ref-type="bibr" rid="bibr7-0884533612467824">7</xref></sup>) and thus may interact with several types of prescription medications,<sup><xref ref-type="bibr" rid="bibr8-0884533612467824">8</xref></sup> potentially altering drug effectiveness or toxicity. Conversely, certain drugs may alter vitamin D metabolism and status.</p>
<p>Supplemental vitamin D is available in 2 forms: cholecalciferol (vitamin D<sub>3</sub>) and ergocalciferol (vitamin D<sub>2</sub>). Vitamin D<sub>3</sub>, produced endogenously in the skin upon exposure to ultraviolet (UV) radiation, is found in fortified foods and foods of animal origin such as fish, eggs, and liver. Vitamin D<sub>2</sub> is only available exogenously, primarily through consumption of plant foods, fortified foods, and dietary supplements. The liver is the primary site for the initial hydroxylation reaction that converts both vitamin D<sub>2</sub> and D<sub>3</sub> to the main circulating form of vitamin D, 25-hydroxycholecalciferol (25(OH)D). This conversion occurs via hepatic 25-hydoxylases, which include the cytochrome P450 (CYP) enzymes 2R1, 3A4, and 27A1. The active steroid hormone form of vitamin D is 1,25-dihydroxycholecalciferol (1,25(OH)<sub>2</sub>D), which is formed from 25(OH)D at both the local tissue level and in the kidney by an additional hydroxylation of 25(OH)D via 1α-hydroxylase (CYP27B1).<sup><xref ref-type="bibr" rid="bibr9-0884533612467824">9</xref></sup> Catabolism of vitamin D metabolites occurs via 24-hydroxylase (CYP24A1). Vitamin D metabolism is depicted in <xref ref-type="fig" rid="fig1-0884533612467824">Figure 1</xref>.</p>
<fig id="fig1-0884533612467824" position="float">
<label>Figure 1.</label>
<caption>
<p>Vitamin D metabolism. Ovals denote metabolic enzymes, rectangles denote substrates.</p>
</caption>
<graphic xlink:href="10.1177_0884533612467824-fig1.tif"/></fig>
<p>As a steroid hormone, 1,25(OH)<sub>2</sub>D is involved in intracellular signaling through both rapid responses (initiation of membrane-associated signal transduction) and genomic responses (initiation/inhibition of transcription for genes containing a vitamin D response element).<sup><xref ref-type="bibr" rid="bibr10-0884533612467824">10</xref></sup> In the slower genomic responses, binding of 1,25(OH)<sub>2</sub>D to the vitamin D receptor in the cytoplasm forms a heterodimer with the retinoid X receptor (RXR), which is then translocated into the nucleus, where it binds to vitamin D receptor elements (VDREs) in the promoter region of certain genes and either activates or inhibits gene transcription (<xref ref-type="fig" rid="fig2-0884533612467824">Figure 2</xref>). Gene expression profiling has shown that 1,25(OH)<sub>2</sub>D enhances transcription of several phase 1<sup><xref ref-type="bibr" rid="bibr11-0884533612467824">11</xref></sup> and phase 2<sup><xref ref-type="bibr" rid="bibr12-0884533612467824">12</xref></sup> biotransformation enzymes, as well as P-glycoprotein (also known as multidrug resistant protein 1),<sup><xref ref-type="bibr" rid="bibr13-0884533612467824">13</xref></sup> enzymes that are involved in drug bioavailability and metabolism.</p>
<fig id="fig2-0884533612467824" position="float">
<label>Figure 2.</label>
<caption><p>Vitamin D intracellular signaling pathways. As a steroid hormone, 1,25(OH)2D is involved in intracellular signaling through both rapid responses (initiation of membrane-associated signal transduction as a result of 1,25[OH]2D binding to membrane-bound vitamin D receptors [mVDR]) and genomic responses (initiation/inhibition of transcription for genes containing a vitamin D response element [VDRE]). In the slower genomic responses, vitamin D metabolites can enter the cell either as 25(OH)D (through carriermediated endocytosis with megalin or cubilin as the primary carriers, and subsequent intracellular conversion to 1,25[OH]2D), or directly as the active 1,25(OH)2D. Binding of 1,25(OH)2D to the vitamin D receptor (VDR) in the cytoplasm forms a heterodimer with the retinoid X receptor (RXR), which is then translocated into the nucleus where it binds to VDREs in the promoter region of certain genes and either activates or inhibits gene transcription in complex with RNA polymerase (RNA Pol).</p></caption>
<graphic xlink:href="10.1177_0884533612467824-fig2.tif"/></fig>
<p>The metabolically active 1,25(OH)<sub>2</sub>D form is tightly regulated at the tissue level and is present in circulation only in picomolar quantities, and thus 25(OH)D is considered the more clinically relevant metabolite for assessing overall vitamin D status. Although the <italic>Dietary Reference Intakes for Vitamin D and Calcium</italic> report, issued in 2011 by the Institute of Medicine, proposes ≥20 ng/mL as the definition of sufficiency based solely on requirements to prevent osteoporosis,<sup><xref ref-type="bibr" rid="bibr14-0884533612467824">14</xref></sup> it has been hypothesized that serum 25(OH)D concentrations of ≥30–32 ng/mL (75–80 nmol/L) are optimal in healthy populations.<sup><xref ref-type="bibr" rid="bibr15-0884533612467824">15</xref><xref ref-type="bibr" rid="bibr16-0884533612467824"/>–<xref ref-type="bibr" rid="bibr17-0884533612467824">17</xref></sup> Lower 25(OH)D levels are commonly reported in obese individuals compared with normal-weight subjects. These findings have been attributed to sequestration of the fat-soluble vitamin D in adipose tissue, the major storage site for vitamin D.<sup><xref ref-type="bibr" rid="bibr18-0884533612467824">18</xref></sup> At latitudes &gt;40° (Minneapolis = 45°N), UV intensity is not strong enough to stimulate cholecalciferol synthesis in the skin during the winter months.<sup><xref ref-type="bibr" rid="bibr19-0884533612467824">19</xref></sup> Several studies show that 25(OH)D concentrations are higher in men than in women, although the reasons for these differences are not known.<sup><xref ref-type="bibr" rid="bibr20-0884533612467824">20</xref></sup> In addition to low dietary/supplemental vitamin D intake and low UV exposure, other factors associated with suboptimal 25(OH)D levels include advanced age and darker skin pigmentation.<sup><xref ref-type="bibr" rid="bibr20-0884533612467824">20</xref>,<xref ref-type="bibr" rid="bibr21-0884533612467824">21</xref></sup></p>
<p>The 25-hydroxylase CYP3A4, which converts ergo- and cholecalciferol to 25(OH)D, is also a phase 1 biotransformation enzyme for many drugs.<sup><xref ref-type="bibr" rid="bibr22-0884533612467824">22</xref></sup> In vitro studies indicate that as many of half of all therapeutic drugs are metabolized by CYP3A4, whereas other drugs may inhibit or induce CYP3A4 activity (<xref ref-type="table" rid="table1-0884533612467824">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr23-0884533612467824">23</xref></sup> CYP3A4 is active in the mucosal enterocytes in the intestines as well as hepatocytes,<sup><xref ref-type="bibr" rid="bibr24-0884533612467824">24</xref>,<xref ref-type="bibr" rid="bibr25-0884533612467824">25</xref></sup> and therefore interactions between orally administered drugs and dietary/supplemental vitamin D intake may be more significant than for intravenously administered drugs or vitamin D synthesized as a result of UV exposure. The CYP3A4 gene also contains a vitamin D response element, and CYP3A4 expression is upregulated in the presence of 1,25(OH)<sub>2</sub>D.<sup><xref ref-type="bibr" rid="bibr26-0884533612467824">26</xref>,<xref ref-type="bibr" rid="bibr27-0884533612467824">27</xref></sup> Thus, vitamin D may alter metabolism of drugs requiring CYP3A4 activation.<sup><xref ref-type="bibr" rid="bibr13-0884533612467824">13</xref></sup></p>
<table-wrap id="table1-0884533612467824" position="float">
<label>Table 1.</label>
<caption>
<p>Examples of Drugs That Are Activated by, Inhibit, or Induce CYP3A4.</p></caption>
<graphic alternate-form-of="table1-0884533612467824" xlink:href="10.1177_0884533612467824-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Substrate for CYP3A4<sup><xref ref-type="bibr" rid="bibr23-0884533612467824">23</xref>,<xref ref-type="bibr" rid="bibr173-0884533612467824">173</xref></sup></th>
<th align="center">Inhibits CYP3A4<sup><xref ref-type="bibr" rid="bibr23-0884533612467824">23</xref>,<xref ref-type="bibr" rid="bibr173-0884533612467824">173</xref>,<xref ref-type="bibr" rid="bibr174-0884533612467824">174</xref></sup></th>
<th align="center">Induces CYP3A4<sup><xref ref-type="bibr" rid="bibr23-0884533612467824">23</xref>,<xref ref-type="bibr" rid="bibr166-0884533612467824">166</xref>,<xref ref-type="bibr" rid="bibr167-0884533612467824">167</xref>,<xref ref-type="bibr" rid="bibr173-0884533612467824">173</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Antidiabetics</td>
<td>Anticonvulsants</td>
</tr>
<tr>
<td> Acetaminophen</td>
<td> Rosiglitazone<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td> Carbamazepine<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Celecoxib</td>
<td>Antidepressants</td>
<td> Phenobarbital</td>
</tr>
<tr>
<td> Codeine</td>
<td> Fluoxetine<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td> Phenytoin<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Fentanyl</td>
<td>Antifungal agents</td>
<td> Primidone</td>
</tr>
<tr>
<td>Antimicrobial agents</td>
<td> Clotrimazole</td>
<td>Antimicrobial agents</td>
</tr>
<tr>
<td> Dapsone</td>
<td> Itraconazole</td>
<td> Erythromycin</td>
</tr>
<tr>
<td> Sulfamethoxazole</td>
<td> Ketoconazole</td>
<td> Quinine<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>Antimicrobial agents</td>
<td> Rifampin<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Nifedipine</td>
<td> Clarithromycin</td>
<td>Diuretics</td>
</tr>
<tr>
<td>Chemotherapeutic agents</td>
<td> Doxycycline</td>
<td> Spironolactone<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Cyclophosphamide</td>
<td> Erythromycin</td>
<td>Chemotherapeutic agents</td>
</tr>
<tr>
<td> Docetaxel</td>
<td> Isoniazid<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td> Cyclophosphamide<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Etoposide</td>
<td> Primaquine</td>
<td> Ifosfamide<sup><xref ref-type="table-fn" rid="table-fn2-0884533612467824">b</xref></sup></td>
</tr>
<tr>
<td> Ifosfamide</td>
<td> Tetracycline</td>
<td> Paclitaxel</td>
</tr>
<tr>
<td> Paclitaxel</td>
<td>Antihypertensives</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td> Vinblastine</td>
<td> Amlodipine<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td> Dexamethasone</td>
</tr>
<tr>
<td> Vinorelbine</td>
<td> Dihydralazine</td>
<td>Vitamins</td>
</tr>
<tr>
<td>Erectile dysfunction</td>
<td> Diltiazem<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td> 1,25(OH)<sub>2</sub>D (calcitriol)</td>
</tr>
<tr>
<td> Sildenafil</td>
<td> Nicardipine</td>
<td/></tr>
<tr>
<td>Gastrointestinal motility</td>
<td> Verapamil<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td/></tr>
<tr>
<td> Cisapride</td>
<td>Chemotherapeutic agents</td>
<td/></tr>
<tr>
<td>Immunosuppressive agents</td>
<td> Irinotecan</td>
<td/></tr>
<tr>
<td> Cyclosporine A</td>
<td> Tamoxifen<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td/></tr>
<tr>
<td> Sirolimus</td>
<td>Erectile dysfunction</td>
<td/></tr>
<tr>
<td> Tacrolimus</td>
<td> Tadalafil<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td/></tr>
<tr>
<td/>
<td>Immunosuppressive agents</td>
<td/></tr>
<tr>
<td/>
<td> Cyclosporine A<sup><xref ref-type="table-fn" rid="table-fn1-0884533612467824">a</xref></sup></td>
<td/></tr>
<tr>
<td/>
<td>Proton-pump inhibitors</td>
<td/></tr>
<tr>
<td/>
<td> Omeprazole</td>
<td/></tr>
<tr>
<td/>
<td>Statins</td>
<td/></tr>
<tr>
<td/>
<td> Atorvastatin</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533612467824">
<label>a</label>
<p>Indicates drugs that are reversible inhibitors of CYP3A4.</p></fn>
<fn id="table-fn2-0884533612467824">
<label>b</label>
<p>Indicates drugs that are able to induce their own metabolism.</p></fn>
</table-wrap-foot></table-wrap>
<p>Other potential biologic mechanisms for drug–vitamin D interactions include (1) altered absorption of the fat-soluble vitamin D when taken concurrently with drugs that inhibit absorption or enhance elimination of dietary fat and (2) exacerbation of the risk of hypercalcemia when taken with calcium-sparing medications.</p>
<p>The purpose of this systematic review is to determine the extent to which drugs affect vitamin D status (by altering absorption, metabolism, or excretion of vitamin D) or the extent to which vitamin D alters drug absorption and metabolism, activity, or toxicity. Specifically, this review focuses on human studies examining noncalcemic/bone mineralization drug–vitamin D interactions.</p>
<sec id="section1-0884533612467824" sec-type="methods">
<title>Methods</title>
<sec id="section2-0884533612467824">
<title>Study Selection</title>
<p>A systematic literature search of electronic databases was conducted for articles published through September 1, 2010. Databases that yielded articles meeting the eligibility criteria were BIOSIS Previews, CAB Abstracts, Cumulative Index of Nursing and Allied Health, Global Health, International Pharmaceutical Abstracts, and Medline.</p>
<p>A search strategy was initially performed using the Medical Subject Headings (MeSH) and keywords <italic>vitamin D, cholecalciferol, ergocalciferol</italic>, and <italic>drug interactions</italic>. Based on articles identified during the initial search, the search terms <italic>colestyramine, statin, antibiotics, cimetidine, anticonvulsants, glucocorticoids, cyclosporins, mineral oils, hormone replacement therapy, weight reduction, mineral oils, diuretics, thiazides, hydroxymethylglutaryl-CoA reductase inhibitors, histamine H2 antagonists, HIV protease inhibitors</italic>, and <italic>immunosuppressive agents</italic> were added in subsequent searches. Additional references within identified primary research or review articles were also examined for eligibility.</p>
<p>Studies were included in the systematic review if they assessed vitamin D intake or concentrations and drug interactions in humans. Reports were excluded if the focus was on vitamin D analogues, osteoporosis treatment, or osteopenia treatment or if vitamin D metabolism was altered as a consequence of the disease process rather than a treatment or an intervention. Animal or cell culture studies were also excluded. Case reports were included for most drug categories, but they were excluded for steroid and antiepileptic drugs because a considerable number of studies with stronger study designs were available for those drug categories.</p>
</sec>
<sec id="section3-0884533612467824">
<title>Data Abstraction and Quality Assessment</title>
<p>Using a standardized data abstraction form, 2 of the authors (K.R., J.M.H.-R.) abstracted data for each trial. A third author (S.J.O.) reviewed the articles and abstraction forms for accuracy of the classification and quality rating. In cases where the third author disagreed with classification and/or rating assigned by the primary reviewer, the study was discussed among the authors until a consensus was reached. The following information was abstracted from each study: first author, year of publication, location of the study, study design, study population, sample size, duration of participant follow-up, drug dose and formulation, effect on 25(OH)D concentrations or drug level/activity, potential confounders evaluated in the study, and study limitations. If a study reported findings related to both 25(OH)D and 1,25(OH)<sub>2</sub>D concentrations, only the data related to 25(OH)D were abstracted.</p>
<p>The American Dietetic Association (ADA) Evidence Analysis classification system and quality criteria checklist<sup><xref ref-type="bibr" rid="bibr28-0884533612467824">28</xref></sup> was used to assign class and quality ratings. The ADA system was chosen because it is oriented toward medical nutrition interventions and is designed to support translation to clinical practice guidelines. Study classification was based on study design, with randomized controlled trials being assigned a classification of A, cohort studies assigned a B classification, case-control and time series studies assigned a C classification, and cross-sectional, case series, case reports, and before-and-after studies assigned a D classification. The quality criteria checklist includes questions in 10 categories relating to the reporting of the research methods and findings: a clear statement of the research question, potential for bias in selection of study participants, comparability of the study groups, methods for handling withdrawals, appropriateness of exposure assessment or the intervention, appropriateness of the outcome assessment, statistical analysis methods, whether the conclusions are supported by the data, and the potential for bias from the study’s funding or sponsorship. Studies that appeared to be free from selection bias, applied appropriate randomization procedures, and had appropriate intervention methods/exposure assessment and outcome measurements received a positive rating. Studies that failed to meet the reporting requirements for 6 or more of the quality criteria categories received a negative rating. All other studies received a neutral rating.</p>
</sec></sec>
<sec id="section4-0884533612467824" sec-type="results">
<title>Results</title>
<p>A total of 1225 reports were identified through the initial search process. Titles were reviewed for eligibility, and 912 manuscripts were excluded at this stage. Abstracts were obtained for the remaining 313 reports. After reviewing the abstracts, 109 unique reports met the full inclusion criteria (<xref ref-type="fig" rid="fig3-0884533612467824">Figure 3</xref>).</p>
<fig id="fig3-0884533612467824" position="float">
<label>Figure 3.</label>
<caption><p>Flow chart of manuscript identification and inclusion.</p></caption>
<graphic xlink:href="10.1177_0884533612467824-fig3.tif"/></fig>
<p>Included studies are summarized in Supplementary Table S1. The majority of the studies were classified as class C (nonrandomized trials, case-control studies, or time series; n = 30, 28%) or D (cross-sectional, trend, case reports/series, or before-and-after studies; n = 69, 63%). Ten of the included studies were randomized controlled trials (RCTs; class A), of which 8 were of neutral quality and 2 were rated as negative quality. None of the included studies were cohort studies (class B). Only 2 of the class C and 3 of the class D studies were found to be of positive quality. All positive quality studies were published after 1996, likely reflecting increasing reporting standards for publication.</p>
<sec id="section5-0884533612467824">
<title>Drugs That Interfere With Vitamin D Absorption</title>
<sec id="section6-0884533612467824">
<title>Bile acid sequestrants</title>
<p>The bile acid sequestrants, colestipol and cholestyramine, reduce cholesterol by binding bile acids in the gastrointestinal tract and preventing reabsorption of the bile acids. Bile acid sequestrants may also bind fat-soluble vitamins, including vitamin D. As vitamin D metabolites are also present in the bile, increased bile acid excretion could reduce body stores of vitamin D.</p>
<p>Three RCTs (class A; 2 neutral quality,<sup><xref ref-type="bibr" rid="bibr29-0884533612467824">29</xref>,<xref ref-type="bibr" rid="bibr30-0884533612467824">30</xref></sup> 1 negative quality<sup><xref ref-type="bibr" rid="bibr31-0884533612467824">31</xref></sup>), 1 time-series study (class C; negative quality<sup><xref ref-type="bibr" rid="bibr32-0884533612467824">32</xref></sup>), and 1 before-and-after study (class D; negative quality<sup><xref ref-type="bibr" rid="bibr33-0884533612467824">33</xref></sup>) evaluated the effect of bile acid sequestrants on vitamin D status. One of the RCTs reported a statistically significant decrease in serum 25(OH)D concentrations among children with familial hypercholesterolemia taking 8 g cholestyramine/d for 1 year compared with controls.<sup><xref ref-type="bibr" rid="bibr30-0884533612467824">30</xref></sup> In contrast, the time-series and before-and-after studies reported no significant change from baseline circulating 25(OH)D levels among children taking colestipol for 2–24 months.<sup><xref ref-type="bibr" rid="bibr32-0884533612467824">32</xref>,<xref ref-type="bibr" rid="bibr33-0884533612467824">33</xref></sup> Similarly, 2 of the RCTs both reported no significant differences in circulating 25(OH)D concentrations between adults taking 24 g cholestyramine/d and a control group after 24 weeks<sup><xref ref-type="bibr" rid="bibr31-0884533612467824">31</xref></sup> or 7–10 years.<sup><xref ref-type="bibr" rid="bibr29-0884533612467824">29</xref></sup> Overall, these studies suggest that bile acid sequestrants do not alter vitamin D status.</p>
</sec>
<sec id="section7-0884533612467824">
<title>Lipase inhibitors</title>
<p>Orlistat is used as a weight loss aid and acts by binding the active sites of gastric and pancreatic lipases within the gastrointestinal tract to block absorption of dietary fats and thus calories.<sup><xref ref-type="bibr" rid="bibr34-0884533612467824">34</xref></sup> As vitamin D is fat soluble, orlistat may also inhibit dietary and supplemental vitamin D absorption.<sup><xref ref-type="bibr" rid="bibr35-0884533612467824">35</xref></sup></p>
<p>Two RCTs (class A; both neutral quality<sup><xref ref-type="bibr" rid="bibr36-0884533612467824">36</xref>,<xref ref-type="bibr" rid="bibr37-0884533612467824">37</xref></sup>) and 1 before-and-after study (class D; negative quality<sup><xref ref-type="bibr" rid="bibr38-0884533612467824">38</xref></sup>) met the inclusion criteria for this drug category. All 3 studies reported decreases in 25(OH)D concentrations among participants receiving orlistat. However, in the RCTs, the control groups also experienced a decrease in 25(OH)D concentrations, suggesting that the decrease in dietary fat intake may be the reason for the decrease in 25(OH)D concentrations rather than the orlistat itself.</p>
<p>Vitamin D status should be monitored for individuals taking orlistat. If deficient, it would be prudent to recommend that these individuals take vitamin D supplements several hours prior to their orlistat dose to maximize vitamin D absorption.</p>
</sec>
</sec>
<sec id="section8-0884533612467824">
<title>Drugs That Interfere With Vitamin D Metabolism</title>
<sec id="section9-0884533612467824">
<title>Statins</title>
<p>Statins lower serum cholesterol concentrations by inhibiting the rate-limiting enzyme in cholesterol synthesis, HMG Co-A reductase.<sup><xref ref-type="bibr" rid="bibr39-0884533612467824">39</xref></sup> Vitamin D is derived from cholesterol, so by decreasing cholesterol synthesis, statins could also reduce vitamin D synthesis.<sup><xref ref-type="bibr" rid="bibr40-0884533612467824">40</xref>,<xref ref-type="bibr" rid="bibr41-0884533612467824">41</xref></sup> Another potential mechanism for vitamin D–statin interactions is competition for CYP3A4 activity. Atorvastatin, lovastatin, and simvastatin are primarily metabolized by CYP3A4.<sup><xref ref-type="bibr" rid="bibr42-0884533612467824">42</xref>,<xref ref-type="bibr" rid="bibr43-0884533612467824">43</xref></sup> Rosuvastatin and fluvastatin are primarily metabolized by CYP2C9.<sup><xref ref-type="bibr" rid="bibr43-0884533612467824">43</xref>,<xref ref-type="bibr" rid="bibr44-0884533612467824">44</xref></sup> Pitavastatin and pravastatin interact minimally with metabolizing enzymes, degrading in the stomach and excreted as parent compound.<sup><xref ref-type="bibr" rid="bibr43-0884533612467824">43</xref>,<xref ref-type="bibr" rid="bibr44-0884533612467824">44</xref></sup></p>
<p>A total of 5 studies on statins and vitamin D status, including 1 RCT (class A; negative quality<sup><xref ref-type="bibr" rid="bibr31-0884533612467824">31</xref></sup>), 1 nonrandomized trial (class C; neutral quality<sup><xref ref-type="bibr" rid="bibr45-0884533612467824">45</xref></sup>) and 2 before-after studies (class D; both negative quality,<sup><xref ref-type="bibr" rid="bibr41-0884533612467824">41</xref></sup> with data from 1 study published in 2 separate publications<sup><xref ref-type="bibr" rid="bibr46-0884533612467824">46</xref>,<xref ref-type="bibr" rid="bibr47-0884533612467824">47</xref></sup>), and 1 cross-sectional study (class D; neutral quality<sup><xref ref-type="bibr" rid="bibr48-0884533612467824">48</xref></sup>) met the inclusion criteria. Three studies reported that atorvastatin therapy increased circulating 25(OH)D.<sup><xref ref-type="bibr" rid="bibr45-0884533612467824">45</xref>,<xref ref-type="bibr" rid="bibr46-0884533612467824">46</xref>,<xref ref-type="bibr" rid="bibr48-0884533612467824">48</xref></sup> One study reported statistically significantly lower concentrations of atorvastatin and its metabolites among participants taking 800 IU/d supplemental vitamin D for 6 weeks compared with those who did not receive supplements (<italic>P</italic> &lt; .05).<sup><xref ref-type="bibr" rid="bibr45-0884533612467824">45</xref></sup> However, cholesterol levels were also lower during vitamin D supplementation despite lower atorvastatin concentrations. The 2 studies evaluating the effect of pravastatin therapy on 25(OH)D concentrations<sup><xref ref-type="bibr" rid="bibr31-0884533612467824">31</xref>,<xref ref-type="bibr" rid="bibr41-0884533612467824">41</xref></sup> both reported no significant differences in 25(OH)D concentrations before and after treatment.</p>
<p>Although further study is needed, it appears that only the statins metabolized by CYP3A4 have the potential to interact with vitamin D supplementation. Clinicians should consider whether it is appropriate to ask patients to discontinue vitamin D supplementation while taking atorvastatin, lovastatin, or simvastatin or whether patients should be switched to a different statin to continue vitamin D supplementation.</p>
</sec>
</sec>
<sec id="section10-0884533612467824">
<title>Antimicrobials</title>
<sec id="section11-0884533612467824">
<title>Rifampin and isoniazid</title>
<p>Rifampin and isoniazid are used in treating tuberculosis (TB). The complex relationship between vitamin D and TB has long been recognized. Prior to the advent of antibiotics, sun exposure and vitamin D supplements formed the primary treatment for the disease.<sup><xref ref-type="bibr" rid="bibr49-0884533612467824">49</xref></sup> Vitamin D is a modulator of macrophage activity and enhances the production of the antimicrobial protein cathelicidin.<sup><xref ref-type="bibr" rid="bibr50-0884533612467824">50</xref></sup> Vitamin D deficiency has been associated with increased susceptibility to TB infection or reactivation of latent TB infections.<sup><xref ref-type="bibr" rid="bibr51-0884533612467824">51</xref></sup> Treatment with rifampin and isoniazid may also alter vitamin D status, as CYP3A4 is induced by rifampin and inhibited by isoniazid.<sup><xref ref-type="bibr" rid="bibr52-0884533612467824">52</xref></sup></p>
<p>Six small time-series studies (class C; all negative quality<sup><xref ref-type="bibr" rid="bibr53-0884533612467824">53</xref><xref ref-type="bibr" rid="bibr54-0884533612467824"/><xref ref-type="bibr" rid="bibr55-0884533612467824"/><xref ref-type="bibr" rid="bibr56-0884533612467824"/><xref ref-type="bibr" rid="bibr57-0884533612467824"/>–<xref ref-type="bibr" rid="bibr58-0884533612467824">58</xref></sup>), each with between 8 and 27 participants, have evaluated the association between rifampin, isoniazid, and vitamin D status. Four studies reported that 25(OH)D decreased,<sup><xref ref-type="bibr" rid="bibr53-0884533612467824">53</xref><xref ref-type="bibr" rid="bibr54-0884533612467824"/><xref ref-type="bibr" rid="bibr55-0884533612467824"/>–<xref ref-type="bibr" rid="bibr56-0884533612467824">56</xref></sup> 1 reported no change,<sup><xref ref-type="bibr" rid="bibr57-0884533612467824">57</xref></sup> and 1 reported increased 25(OH)D<sup><xref ref-type="bibr" rid="bibr58-0884533612467824">58</xref></sup> after rifampin and/or isoniazid treatment. Several of the studies noted that the individuals with TB had below-normal 25(OH)D concentrations pretreatment.<sup><xref ref-type="bibr" rid="bibr56-0884533612467824">56</xref>,<xref ref-type="bibr" rid="bibr57-0884533612467824">57</xref></sup> Although some of the studies considered the season in which vitamin D status was assessed, few considered dietary or supplemental vitamin D intake, and none assessed UV exposure or stratified by race/skin tone. Thus, it is prudent to monitor 25(OH)D concentrations during rifampin and isoniazid treatment, but if vitamin D deficiency is noted, it may be due to decreased vitamin D exposure rather than a true drug-nutrient interaction.</p>
</sec>
<sec id="section12-0884533612467824">
<title>Hydroxychloroquine</title>
<p>Hydroxychloroquine is used in the treatment of malaria, as well as autoimmune disorders such as systemic lupus erythematosus (SLE). Because individuals with autoimmune diseases often also have photosensitivity and avoid sun exposure, there has been concern that vitamin D deficiency might be common in this population.</p>
<p>One cross-sectional study with a comparison group (class D; neutral quality<sup><xref ref-type="bibr" rid="bibr59-0884533612467824">59</xref></sup>) evaluated the prevalence and predictors of vitamin D deficiency (defined as serum 25(OH)D &lt;10 ng/mL) among 92 adults with SLE. The researchers found that vitamin D deficiency is common among individuals with SLE (n = 69, 75%), and individuals taking hydroxychloroquine had higher 25(OH)D concentrations compared with those who were not taking hydroxychloroquine, which the authors hypothesized may be due to a decreased rate of conversion of 25(OH)D to 1,25(OH)<sub>2</sub>D.<sup><xref ref-type="bibr" rid="bibr59-0884533612467824">59</xref></sup></p>
</sec>
<sec id="section13-0884533612467824">
<title>Antiepileptic drugs</title>
<p>Physicians have long noted a higher incidence of osteopenia and osteoporosis among patients on antiepileptic drugs (AEDs), but the mechanism by which this occurs is not entirely clear. Cell culture studies have shown that phenobarbital (PB), phenytoin (PHT), primidone (PRM), carbamazepine (CBZ), oxcarbazepine, and felbamate induce CYP3A4 expression, whereas ethosuximide (ETHS), valproic acid (VPA), and lamotrigine (LTG) have no effect on CYP3A4 activity.<sup><xref ref-type="bibr" rid="bibr60-0884533612467824">60</xref>,<xref ref-type="bibr" rid="bibr61-0884533612467824">61</xref></sup> PB and PHT have also been found to increase CYP24A expression,<sup><xref ref-type="bibr" rid="bibr61-0884533612467824">61</xref>,<xref ref-type="bibr" rid="bibr62-0884533612467824">62</xref></sup> which could result in increased clearance of vitamin D metabolites and lower serum 25(OH)D levels.</p>
<p>In total, 46 studies have evaluated the effect of AEDs on vitamin D status, but most were small single-institution reports, and only 4 of these studies included more than 100 participants.<sup><xref ref-type="bibr" rid="bibr63-0884533612467824">63</xref><xref ref-type="bibr" rid="bibr64-0884533612467824"/><xref ref-type="bibr" rid="bibr65-0884533612467824"/>–<xref ref-type="bibr" rid="bibr66-0884533612467824">66</xref></sup> The majority of included studies were cross-sectional with (class D; 1 positive quality,<sup><xref ref-type="bibr" rid="bibr67-0884533612467824">67</xref></sup> 17 neutral quality,<sup><xref ref-type="bibr" rid="bibr63-0884533612467824">63</xref>,<xref ref-type="bibr" rid="bibr68-0884533612467824">68</xref><xref ref-type="bibr" rid="bibr69-0884533612467824"/><xref ref-type="bibr" rid="bibr70-0884533612467824"/><xref ref-type="bibr" rid="bibr71-0884533612467824"/><xref ref-type="bibr" rid="bibr72-0884533612467824"/><xref ref-type="bibr" rid="bibr72-0884533612467824"/><xref ref-type="bibr" rid="bibr73-0884533612467824"/><xref ref-type="bibr" rid="bibr74-0884533612467824"/><xref ref-type="bibr" rid="bibr75-0884533612467824"/><xref ref-type="bibr" rid="bibr76-0884533612467824"/><xref ref-type="bibr" rid="bibr77-0884533612467824"/><xref ref-type="bibr" rid="bibr78-0884533612467824"/><xref ref-type="bibr" rid="bibr79-0884533612467824"/><xref ref-type="bibr" rid="bibr80-0884533612467824"/><xref ref-type="bibr" rid="bibr81-0884533612467824"/><xref ref-type="bibr" rid="bibr82-0884533612467824"/>–<xref ref-type="bibr" rid="bibr83-0884533612467824">83</xref></sup> and 13 negative quality<sup><xref ref-type="bibr" rid="bibr64-0884533612467824">64</xref><xref ref-type="bibr" rid="bibr65-0884533612467824"/>–<xref ref-type="bibr" rid="bibr66-0884533612467824">66</xref>,<xref ref-type="bibr" rid="bibr84-0884533612467824">84</xref><xref ref-type="bibr" rid="bibr85-0884533612467824"/><xref ref-type="bibr" rid="bibr86-0884533612467824"/><xref ref-type="bibr" rid="bibr87-0884533612467824"/><xref ref-type="bibr" rid="bibr88-0884533612467824"/><xref ref-type="bibr" rid="bibr89-0884533612467824"/><xref ref-type="bibr" rid="bibr90-0884533612467824"/><xref ref-type="bibr" rid="bibr91-0884533612467824"/><xref ref-type="bibr" rid="bibr92-0884533612467824"/>–<xref ref-type="bibr" rid="bibr93-0884533612467824">93</xref></sup>) or without a comparison group (class D; 3 neutral quality,<sup><xref ref-type="bibr" rid="bibr94-0884533612467824">94</xref><xref ref-type="bibr" rid="bibr95-0884533612467824"/>–<xref ref-type="bibr" rid="bibr96-0884533612467824">96</xref></sup> 2 negative quality<sup><xref ref-type="bibr" rid="bibr97-0884533612467824">97</xref>,<xref ref-type="bibr" rid="bibr98-0884533612467824">98</xref></sup>). The 10 remaining studies were 7 time-series studies with (class C; 3 neutral quality,<sup><xref ref-type="bibr" rid="bibr99-0884533612467824">99</xref><xref ref-type="bibr" rid="bibr100-0884533612467824"/>–<xref ref-type="bibr" rid="bibr101-0884533612467824">101</xref></sup> 2 negative quality<sup><xref ref-type="bibr" rid="bibr102-0884533612467824">102</xref>,<xref ref-type="bibr" rid="bibr103-0884533612467824">103</xref></sup>) or without comparison groups (class C; 2 neutral quality<sup><xref ref-type="bibr" rid="bibr104-0884533612467824">104</xref>,<xref ref-type="bibr" rid="bibr105-0884533612467824">105</xref></sup>) and 3 before-and-after studies (class D; 1 positive quality,<sup><xref ref-type="bibr" rid="bibr106-0884533612467824">106</xref></sup> 1 neutral quality,<sup><xref ref-type="bibr" rid="bibr107-0884533612467824">107</xref></sup> 1 negative quality<sup><xref ref-type="bibr" rid="bibr108-0884533612467824">108</xref></sup>).</p>
<p>Study design limitations likely contributed to variation in the findings across the 46 studies. Most of the studies that compared AED users with non-AED users found AED use to be associated with lower serum 25(OH)D concentrations,<sup><xref ref-type="fn" rid="fn1-0884533612467824">*</xref></sup> but 2 of these studies reported that the difference in 25(OH)D concentrations between AED users and controls occurred only in the winter months.<sup><xref ref-type="bibr" rid="bibr76-0884533612467824">76</xref>,<xref ref-type="bibr" rid="bibr102-0884533612467824">102</xref></sup> Seven studies reported no significant differences in 25(OH)D concentrations between AED users and nonusers.<sup><xref ref-type="fn" rid="fn2-0884533612467824">†</xref></sup> Most of the participants in these studies were ambulatory rather than institutionalized AED users, and 2 of the studies were conducted in lower latitude countries.<sup><xref ref-type="bibr" rid="bibr82-0884533612467824">82</xref>,<xref ref-type="bibr" rid="bibr85-0884533612467824">85</xref></sup> Unexpectedly, 1 study reported that the individuals on AEDs had higher 25(OH)D concentrations compared with the controls,<sup><xref ref-type="bibr" rid="bibr92-0884533612467824">92</xref></sup> which the authors attributed to adequate sun exposure given that the study participants lived in Florida.</p>
<p>Many studies combined the data for individuals who were on a variety of different single or multidrug AED regimens and did not adjust for dose or duration of AED use. Of the few studies that reported the effects of specific AEDs on 25(OH)D concentrations, no statistically significant differences in 25(OH)D concentrations were observed between those on the CYP3A4-inducing AEDs compared with normal controls<sup><xref ref-type="bibr" rid="bibr66-0884533612467824">66</xref></sup> or within individuals over time.<sup><xref ref-type="bibr" rid="bibr107-0884533612467824">107</xref></sup> One study reported no statistically significant difference in 25(OH)D concentrations among individuals on CYP3A4-inducing AEDs compared with those on other AEDs.<sup><xref ref-type="bibr" rid="bibr96-0884533612467824">96</xref></sup> Overall, the literature suggests that the effect of AEDs on vitamin D status may be evident only among individuals with insufficient exposure to exogenous sources of vitamin D (diet, supplements, or UV exposure).</p>
</sec>
<sec id="section14-0884533612467824">
<title>Corticosteroids</title>
<p>Glucocorticoids, such as prednisone, hydrocortisone, and dexamethasone, are used pharmacologically for a variety of clinical applications, including adrenal replacement, immune suppression, and chemotherapy. However, osteoporosis is a well-known complication of corticosteroid therapy. Alterations in vitamin D metabolism have been investigated as a possible mechanism.</p>
<p>Two RCTs (class A; both neutral quality<sup><xref ref-type="bibr" rid="bibr110-0884533612467824">110</xref>,<xref ref-type="bibr" rid="bibr111-0884533612467824">111</xref></sup>), 4 time-series studies (class C; 3 neutral quality,<sup><xref ref-type="bibr" rid="bibr112-0884533612467824">112</xref><xref ref-type="bibr" rid="bibr113-0884533612467824"/>–<xref ref-type="bibr" rid="bibr114-0884533612467824">114</xref></sup> 1 positive quality<sup><xref ref-type="bibr" rid="bibr115-0884533612467824">115</xref></sup>), and 5 cross-sectional studies (class D; 1 negative,<sup><xref ref-type="bibr" rid="bibr116-0884533612467824">116</xref></sup> 3 neutral,<sup><xref ref-type="bibr" rid="bibr117-0884533612467824">117</xref><xref ref-type="bibr" rid="bibr118-0884533612467824"/>–<xref ref-type="bibr" rid="bibr119-0884533612467824">119</xref></sup> 1 positive quality<sup><xref ref-type="bibr" rid="bibr120-0884533612467824">120</xref></sup>) have evaluated the effect of prednisone therapy on 25(OH)D concentrations. The majority found no difference in 25(OH)D concentrations in comparison to either pretreatment concentrations or to a control group.<sup><xref ref-type="bibr" rid="bibr111-0884533612467824">111</xref><xref ref-type="bibr" rid="bibr112-0884533612467824"/>–<xref ref-type="bibr" rid="bibr113-0884533612467824">113</xref>,<xref ref-type="bibr" rid="bibr116-0884533612467824">116</xref>,<xref ref-type="bibr" rid="bibr117-0884533612467824">117</xref>,<xref ref-type="bibr" rid="bibr119-0884533612467824">119</xref></sup> Lems et al<sup><xref ref-type="bibr" rid="bibr114-0884533612467824">114</xref></sup> reported that 25(OH)D concentrations decreased after low-dose prednisone treatment among healthy controls, which they attributed to seasonal effects given that the study concluded in the fall. In a study of 50 adult rheumatoid arthritis (RA) patients on low-dose prednisone, Lund et al<sup><xref ref-type="bibr" rid="bibr118-0884533612467824">118</xref></sup> also found that 25(OH)D concentrations were significantly lower than the laboratory’s normal values, although none of the study participants were considered deficient. The decreased concentrations may be explained by the fact that the study participants were likely older than the subjects used to establish the laboratory norms. The authors also appropriately note that photosensitivity is a common complication of glucocorticoids and other RA treatments, and the study participants may have been more likely than the general population to avoid sun exposure.</p>
<p>Two studies of prednisolone, one RCT (class A; neutral quality<sup><xref ref-type="bibr" rid="bibr121-0884533612467824">121</xref></sup>) and 1 time-series study (class C; neutral quality<sup><xref ref-type="bibr" rid="bibr122-0884533612467824">122</xref></sup>), both found no statistically significant differences in 25(OH)D concentrations pre- vs posttreatment. Six studies, all cross-sectional (class D; 1 negative,<sup><xref ref-type="bibr" rid="bibr123-0884533612467824">123</xref></sup> 5 neutral quality<sup><xref ref-type="bibr" rid="bibr124-0884533612467824">124</xref><xref ref-type="bibr" rid="bibr125-0884533612467824"/><xref ref-type="bibr" rid="bibr126-0884533612467824"/><xref ref-type="bibr" rid="bibr126-0884533612467824"/>–<xref ref-type="bibr" rid="bibr128-0884533612467824">128</xref></sup>), did not specify the type of glucocorticoid that the participant received. One study comparing 31 adult RA patients on corticosteroids for at least 6 months (2.5–10 mg prednisone equivalents/d) with 38 healthy controls found that the corticosteroid users had significantly lower 25(OH)D concentrations compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr124-0884533612467824">124</xref></sup> Similarly, 2 studies of children and young adults found that individuals with low 25(OH)D concentrations had significantly higher lifetime cumulative glucocorticoid exposure compared with those with higher 25(OH)D concentrations.<sup><xref ref-type="bibr" rid="bibr125-0884533612467824">125</xref>,<xref ref-type="bibr" rid="bibr126-0884533612467824">126</xref></sup> However, the remaining 3 studies, 1 in adults<sup><xref ref-type="bibr" rid="bibr123-0884533612467824">123</xref></sup> and 2 in children,<sup><xref ref-type="bibr" rid="bibr127-0884533612467824">127</xref>,<xref ref-type="bibr" rid="bibr128-0884533612467824">128</xref></sup> found no significant differences in 25(OH)D concentrations between individuals receiving glucocorticoids and controls or laboratory normal values.</p>
<p>Overall, the studies evaluating the effect of glucocorticoids on vitamin D status suggest that 25(OH)D concentrations are not significantly affected by glucocorticoids and that the observed association with osteoporosis/osteopenia may be related to drug effects on other parameters of bone metabolism.<sup><xref ref-type="bibr" rid="bibr113-0884533612467824">113</xref></sup> Few of these studies considered potential differences in the glucocorticoid–vitamin D association by body composition, dietary or supplemental vitamin D intake, or UV exposure.</p>
</sec>
<sec id="section15-0884533612467824">
<title>Immunosuppressive Agents</title>
<p>Immunosuppressive agents, such as cyclosporine and tacrolimus, inhibit T-cell activation and are used to decrease the risk of rejection of the transplanted tissue following solid organ and hematopoietic cell transplantation. Lower doses of these drugs are also used to treat autoimmune disorders. Osteoporosis is a common long-term side effect, especially among transplant patients who often receive both immunosuppressive agents and steroids.</p>
</sec>
<sec id="section16-0884533612467824">
<title>Cyclosporine</title>
<p>Data from cell culture and animal models indicate that cyclosporine inhibits CYP27A1<sup><xref ref-type="bibr" rid="bibr129-0884533612467824">129</xref><xref ref-type="bibr" rid="bibr130-0884533612467824"/><xref ref-type="bibr" rid="bibr131-0884533612467824"/><xref ref-type="bibr" rid="bibr132-0884533612467824"/>–<xref ref-type="bibr" rid="bibr133-0884533612467824">133</xref></sup> and decreases expression of the vitamin D receptor (VDR) and CYP24,<sup><xref ref-type="bibr" rid="bibr133-0884533612467824">133</xref></sup> which would suggest that cyclosporine could alter circulating 25(OH)D concentrations. One RCT (class A; neutral quality<sup><xref ref-type="bibr" rid="bibr134-0884533612467824">134</xref></sup>) and 5 time-series studies (class C; 1 positive quality,<sup><xref ref-type="bibr" rid="bibr135-0884533612467824">135</xref></sup> 1 neutral quality,<sup><xref ref-type="bibr" rid="bibr136-0884533612467824">136</xref></sup> 3 negative quality<sup><xref ref-type="bibr" rid="bibr137-0884533612467824">137</xref><xref ref-type="bibr" rid="bibr138-0884533612467824"/>–<xref ref-type="bibr" rid="bibr139-0884533612467824">139</xref></sup>) evaluated the effect of cyclosporine on vitamin D status. None of the studies reported significant differences in 25(OH)D concentrations when comparing the effect of cyclosporine alone or in combination with prednisone.</p>
</sec>
<sec id="section17-0884533612467824">
<title>Tacrolimus</title>
<p>Tacrolimus is metabolized by CYP3A4 and CYP3A5<sup><xref ref-type="bibr" rid="bibr140-0884533612467824">140</xref></sup> and thus may also be associated with altered 25(OH)D concentrations. One time-series study (class C; negative quality) evaluated the effect of tacrolimus on vitamin D status in individuals who had undergone renal transplantation.<sup><xref ref-type="bibr" rid="bibr139-0884533612467824">139</xref></sup> Again, 25(OH)D concentrations were not significantly different from those of the healthy control group at any of the study time points.</p>
<p>Although it does not appear that cyclosporine or tacrolimus alters vitamin D status, osteopenia and osteoporosis are common among this patient population. Thus, it is prudent to monitor vitamin D concentrations in individuals receiving these drugs and provide supplements as needed to maintain adequate 25(OH)D concentrations. It is likely that the underlying disease state or factors associated with treatment may keep individuals from obtaining adequate vitamin D exposure from sunlight, diet, or supplements, rather than a true effect of the immunosuppressant itself on vitamin D status.</p>
</sec>
<sec id="section18-0884533612467824">
<title>Chemotherapeutic agents</title>
<p>A number of chemotherapeutic agents are metabolized by CYP3A4, including etoposide, epipodophyllotoxin, cyclosphosphamide, ifosfamide, vincristine, vinblastine, paclitasel, docetaxel, irinotecan, tamoxifen, and imatinib,<sup><xref ref-type="bibr" rid="bibr141-0884533612467824">141</xref></sup> and thus may interact with vitamin D. However, few have been extensively studied with respect to their effect on vitamin D status to date.</p>
<p>Two time-series studies (class C; 1 neutral quality,<sup><xref ref-type="bibr" rid="bibr142-0884533612467824">142</xref></sup> 1 negative quality<sup><xref ref-type="bibr" rid="bibr143-0884533612467824">143</xref></sup>) and 1 cross-sectional study (class D; neutral quality<sup><xref ref-type="bibr" rid="bibr144-0884533612467824">144</xref></sup>) evaluated vitamin D status during chemotherapy. All 3 studies reported no significant changes in 25(OH)D concentrations during treatment of breast, ovarian, uterine, or colorectal cancers with a number of different chemotherapeutic agents (cisplatin, 5-fluorouracil, epirubicin, irinotecan, oxaliplatin, capecitabine, and several monoclonal antibodies). Given the small number of study participants in the studies to date and the large number of different (often multiagent) regimens used for cancer treatment, further research is needed. However, because of the high likelihood of vitamin D deficiency due to suboptimal dietary/supplemental intake and decreased UV exposure, vitamin D status should be monitored regularly for patients undergoing cancer treatment.</p>
</sec>
<sec id="section19-0884533612467824">
<title>Highly active antiretroviral agents</title>
<p>Highly active antiretroviral therapy (HAART) includes a broad category of antiretroviral drugs that inhibit various stages of the human immunodeficiency virus (HIV) life cycle and include nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and entry inhibitors.<sup><xref ref-type="bibr" rid="bibr145-0884533612467824">145</xref></sup> In vitro studies have indicated that HAARTs are metabolized by CYP3A4 and can either induce or inhibit CYP3A4 activity,<sup><xref ref-type="bibr" rid="bibr146-0884533612467824">146</xref></sup> and thus drug-induced induction or inhibition of CYP3A4 could alter rates of 25(OH)D synthesis and degradation. Cozzolino et al<sup><xref ref-type="bibr" rid="bibr147-0884533612467824">147</xref></sup> reported that conversion of vitamin D<sub>3</sub> to 25(OH)D and 1,25(OH)<sub>2</sub>D, and degradation of the 1,25(OH)<sub>2</sub>D metabolite were inhibited in human hepatocyte cell cultures exposed to PIs. However, evidence of HAART inhibiting vitamin D bioactivation in humans is currently limited and inconclusive.</p>
<p>Three cross-sectional studies (Class D; 2 neutral quality,<sup><xref ref-type="bibr" rid="bibr148-0884533612467824">148</xref>,<xref ref-type="bibr" rid="bibr149-0884533612467824">149</xref></sup> 1 negative quality<sup><xref ref-type="bibr" rid="bibr150-0884533612467824">150</xref></sup>) met the inclusion criteria for this drug category. The 2 Spanish studies reported lower serum 25(OH)D concentrations among individuals on HAART compared with those who were not on HAART,<sup><xref ref-type="bibr" rid="bibr148-0884533612467824">148</xref>,<xref ref-type="bibr" rid="bibr150-0884533612467824">150</xref></sup> but the difference was statistically significant only in 1 study.<sup><xref ref-type="bibr" rid="bibr148-0884533612467824">148</xref></sup> The other study<sup><xref ref-type="bibr" rid="bibr149-0884533612467824">149</xref></sup> reported that half of the 44 study participants on HAART had deficient 25(OH)D levels (&lt;34 ng/dL), but this study did not include a non-HAART comparison group.</p>
<p>Given the in vitro data suggesting that vitamin D status might be affected by HAART medications, vitamin D status should be monitored in individuals receiving HAART. Future research in this area should consider body composition changes as a potential covariate affecting vitamin D status. Lipodystrophy, a well-described side effect of HAART, characterized by alterations in adipose tissue deposition, may also contribute to alterations in circulating 25(OH)D concentrations.</p>
</sec>
<sec id="section20-0884533612467824">
<title>Histamine H<sub>2</sub>-receptor antagonists</title>
<p>The histamine H<sub>2</sub>-receptor antagonist, cimetidine, inhibits gastric acid secretion by inhibiting histamine stimulation of the gastric parietal cells. However, animal data show that cimetidine also inhibits CYP enzymes, including the 25-hydroxylases.<sup><xref ref-type="bibr" rid="bibr151-0884533612467824">151</xref>,<xref ref-type="bibr" rid="bibr152-0884533612467824">152</xref></sup> One time-series study (class C; neutral quality) of 9 adults with gastric ulcers found no significant change from baseline serum 25(OH)D concentrations while participants were taking cimetidine, yet serum 25(OH)D concentrations rose significantly once cimetidine was discontinued.<sup><xref ref-type="bibr" rid="bibr153-0884533612467824">153</xref></sup> Without a placebo control or other similar studies published, this finding must be interpreted with caution. Ranitidine, another histamine H<sub>2</sub>-receptor antagonist, has not been shown to interact with the CYP enzymes in animal models.<sup><xref ref-type="bibr" rid="bibr154-0884533612467824">154</xref></sup></p>
</sec></sec>
<sec id="section21-0884533612467824">
<title>Drug–Vitamin D Interactions That Induce Side Effects</title>
<sec id="section22-0884533612467824">
<title>Thiazides</title>
<p>Thiazide diuretics are prescribed to reduce blood pressure, treat edema or fluid retention, treat diabetes insipidus, or prevent kidney stones in patients with hypercalciuria. Thiazides reduce the reabsorption of electrolytes from the renal tubules, increase the excretion of electrolytes and fluid, and reduce the excretion of calcium. The combination of thiazide diuretics (decreases urinary calcium excretion) and vitamin D supplementation (enhances intestinal calcium absorption) may theoretically cause or exacerbate hypercalcemia.<sup><xref ref-type="bibr" rid="bibr155-0884533612467824">155</xref></sup></p>
<p>Excluding reports of patients with altered calcium metabolism due to idiopathic osteoporosis or hyperparathyroidism,<sup><xref ref-type="bibr" rid="bibr156-0884533612467824">156</xref><xref ref-type="bibr" rid="bibr157-0884533612467824"/><xref ref-type="bibr" rid="bibr158-0884533612467824"/>–<xref ref-type="bibr" rid="bibr159-0884533612467824">159</xref></sup> 3 cases of hypercalcemia while on thiazides have been reported in 2 studies (class D; 1 positive quality,<sup><xref ref-type="bibr" rid="bibr160-0884533612467824">160</xref></sup> 1 negative quality<sup><xref ref-type="bibr" rid="bibr161-0884533612467824">161</xref></sup>), including a 78-year-old woman taking vitamin D<sub>2</sub> (50,000 IU/d), calcium carbonate (1.5 g elemental calcium/d), and hydrochlorothiazide (25 mg/d)<sup><xref ref-type="bibr" rid="bibr160-0884533612467824">160</xref></sup>; an 87-year-old woman taking vitamin D (dose not specified) and calcium carbonate antacids (1.9 g elemental calcium/d) along with hydrochlorothiazide (50 mg/d)<sup><xref ref-type="bibr" rid="bibr161-0884533612467824">161</xref></sup>; and an 88-year-old woman taking vitamin D (1000 IU/d) and calcium carbonate antacids (3.8 g elemental calcium/d) along with hydrochlorothiazide (50 mg/d).<sup><xref ref-type="bibr" rid="bibr161-0884533612467824">161</xref></sup> These cases were reversible after rehydration and withdrawing the calcium and vitamin D supplementation and the thiazide diuretic. Clinicians should be aware that the combination of thiazide diuretics and vitamin D supplementation may cause hypercalcemia, especially in at-risk individuals, such as the elderly and individuals with compromised renal function or hyperparathyroidism.</p>
<p>Four additional reports evaluated the effect of thiazide diuretics on serum 25(OH)D concentrations, including 1 RCT (class A; negative quality<sup><xref ref-type="bibr" rid="bibr162-0884533612467824">162</xref></sup>), 1 nonrandomized crossover trial (class C; negative quality<sup><xref ref-type="bibr" rid="bibr163-0884533612467824">163</xref></sup>), and 1 before-and-after study<sup><xref ref-type="bibr" rid="bibr164-0884533612467824">164</xref></sup> and 1 cross-sectional study<sup><xref ref-type="bibr" rid="bibr165-0884533612467824">165</xref></sup> (both class D; negative quality). None of the studies reported significant alterations in 25(OH)D concentrations as a result of thiazide treatment.</p>
</sec></sec>
</sec>
<sec id="section23-0884533612467824" sec-type="discussion">
<title>Discussion</title>
<p>This systematic review found insufficient evidence to determine whether lipase inhibitors, antimicrobial agents, antiepileptic drugs, HAART, or H<sub>2</sub>-receptor antagonists alter serum 25(OH)D concentrations. Atorvastatin appears to increase 25(OH)D concentrations, whereas concurrent vitamin D supplementation decreases concentrations of atorvastatin. Use of thiazide diruetics in combination with calcium and vitamin D supplements may induce hypercalcemia in the elderly or those with compromised renal function or hyperparathyroidism.</p>
<p>The area of drug–vitamin D interactions is a clear example of a situation where lack of evidence does not equate to “no harm.” The available research to date has primarily focused on drugs that are commonly associated with osteoporosis (suggesting a potential effect on vitamin D metabolism) or where case reports of adverse outcomes have been reported in the medical literature. Recent advances in understanding the mechanistic details of CYP3A4-mediated drug metabolism and a growing appreciation of the role of vitamin D in CYP3A4 expression will likely lead to a systematic evaluation of potential interactions among drugs that are metabolized by CYP3A4, as well as those metabolized by CYP2R1, CYP27A, CYP27B, and CYP24.</p>
<p>There is also a need for further research to understand the impact of drugs that inhibit CYP enzyme activity related to vitamin D status. For example, synthetic azole drugs, such as the antimicrobial agent ketoconazole and proton-pump inhibitor omeprazole, have been shown to inhibit both CYP3A4<sup>166,<xref ref-type="bibr" rid="bibr167-0884533612467824">167</xref></sup> and CYP24<sup><xref ref-type="bibr" rid="bibr168-0884533612467824">168</xref></sup> in vitro, yet no studies to date have evaluated the effect of these drugs on human vitamin D status.</p>
<p>The currently available literature on drug–vitamin D interactions has a number of limitations, as reflected in the number of neutral and negative quality ratings assigned in this review. Much of the literature to date is based on small case-control studies, case studies, or secondary analyses of clinical data collected for other reasons. Many of the studies were hospital based and lacked relevant comparison groups. Most studies failed to evaluate dietary or supplemental vitamin D intake and sun exposure as potential effect modifiers. And very few studies considered body weight or composition as a potential confounder affecting both vitamin D concentrations and drug response. The majority of studies also lacked statistical power to adjust for appropriate covariates or rule out false-negative findings. For many of the studies where individuals taking a drug were found to have lower 25(OH)D levels than a nondrug comparison group, the lack of data collection on vitamin D intake and UV exposure makes it difficult to determine whether the observed vitamin D deficiency is due to insufficient intake or due to the drug itself.</p>
<p>Because vitamin D is highly hydrophobic and has several metabolites, serum vitamin D determinations are technically challenging. Methodology for assessing vitamin D status has improved significantly in recent years, and the older data reported in many of the studies included in this systematic review may not be accurate or comparable to more current data. Currently, high-performance liquid chromatography (HPLC) or liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is considered the gold-standard technique, although when performed by experienced users, radioimmunoassay (RIA) techniques correlate very closely with LC-MS/MS.<sup><xref ref-type="bibr" rid="bibr169-0884533612467824">169</xref></sup> Commercially available testing kits have been found to produce highly variable results when performed by inexperienced users.<sup><xref ref-type="bibr" rid="bibr170-0884533612467824">170</xref></sup> As a result of regional surveys revealing significant variation between laboratories, an international standardization group, the vitamin D External Quality Assessment Scheme (DEQAS), was started in 1989.<sup><xref ref-type="bibr" rid="bibr171-0884533612467824">171</xref></sup> In 2009, the US National Institute of Standards and Technology (NIST) developed a vitamin D standard (standard reference material 972, Vitamin D in Human Serum) with certified and reference values for 25(OH)D<sub>2</sub>, 25(OH)D<sub>3</sub>, and 3-epi-25(OH)D<sub>3</sub>.<sup><xref ref-type="bibr" rid="bibr172-0884533612467824">172</xref></sup> Supplies of this standard quickly sold out, and NIST does not plan to continue producing this standard due to difficulties in formulating the product. A companion NIST product, SRM 2972, is a set of ethanol-based calibration solutions and has certified values for 25(OH)D<sub>2</sub> and 25(OH)D<sub>3</sub>, which is currently available. NIST has also established a Vitamin D Metabolites Quality Assurance Program (VitDQAP; <ext-link ext-link-type="uri" xlink:href="http://www.nist.gov/mml/analytical/vitdqap.cfm">http://www.nist.gov/mml/analytical/vitdqap.cfm</ext-link>) in collaboration with the National Institutes of Health (NIH) Office of Dietary Supplements (ODS).</p>
<p>Given the increasing prevalence of vitamin D supplementation in the general population, continued evaluation of potential drug–vitamin D interactions is warranted. Larger studies with stronger study designs are needed to clarify potential drug–vitamin D interactions. Future research in this area should address the limitations identified in this review, specifically with prospective data collection including assessment of vitamin D exposure and potential confounding factors such as body weight/composition and seasonality/UV exposure. Future studies should also use standardized vitamin D assay methodologies in a laboratory that participates in external quality assessment protocols specific to vitamin D. Until further research is available, healthcare professionals should be aware of the potential for drug–vitamin D interactions, assess their clients’ use of dietary supplements, and monitor serum 25(OH)D concentrations where indicated with the ultimate goal of achieving adequate serum 25(OH)D concentrations while optimizing drug efficacy and minimizing drug toxicity.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: Support for SJO was provided by training grant T32 CA132670 from the National Cancer Institute. Support for JMH-R was provided by a Faculty Research and Scholarly Activities Grant from St. Catherine University, St. Paul, MN.</p>
</fn>
<fn fn-type="supplementary-material">
<p>Supplementary material for this article is available on the <italic>Nutrition in Clinical Practice</italic> website at <ext-link ext-link-type="uri" xlink:href="http://ncp.sagepub.com/supplemental">http://ncp.sagepub.com/supplemental</ext-link>.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on January 10, 2013.</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="other" id="fn1-0884533612467824">
<label>*</label>
<p>References <sup><xref ref-type="bibr" rid="bibr63-0884533612467824">63</xref>, <xref ref-type="bibr" rid="bibr64-0884533612467824">64</xref>, <xref ref-type="bibr" rid="bibr66-0884533612467824">66</xref>, <xref ref-type="bibr" rid="bibr68-0884533612467824">68</xref><xref ref-type="bibr" rid="bibr69-0884533612467824"/><xref ref-type="bibr" rid="bibr70-0884533612467824"/><xref ref-type="bibr" rid="bibr71-0884533612467824"/><xref ref-type="bibr" rid="bibr72-0884533612467824"/>–<xref ref-type="bibr" rid="bibr74-0884533612467824">74</xref>, <xref ref-type="bibr" rid="bibr76-0884533612467824">76</xref><xref ref-type="bibr" rid="bibr77-0884533612467824"/>–<xref ref-type="bibr" rid="bibr78-0884533612467824">78</xref>, <xref ref-type="bibr" rid="bibr81-0884533612467824">81</xref>, <xref ref-type="bibr" rid="bibr84-0884533612467824">84</xref>, <xref ref-type="bibr" rid="bibr86-0884533612467824">86</xref>, <xref ref-type="bibr" rid="bibr88-0884533612467824">88</xref><xref ref-type="bibr" rid="bibr89-0884533612467824"/>–<xref ref-type="bibr" rid="bibr90-0884533612467824">90</xref>, <xref ref-type="bibr" rid="bibr93-0884533612467824">93</xref>, <xref ref-type="bibr" rid="bibr99-0884533612467824">99</xref>, <xref ref-type="bibr" rid="bibr100-0884533612467824">100</xref>, <xref ref-type="bibr" rid="bibr102-0884533612467824">102</xref>, <xref ref-type="bibr" rid="bibr109-0884533612467824">109</xref></sup>.</p>
</fn>
<fn fn-type="other" id="fn2-0884533612467824">
<label>†</label>
<p>References <sup><xref ref-type="bibr" rid="bibr64-0884533612467824">64</xref>, <xref ref-type="bibr" rid="bibr65-0884533612467824">65</xref>, <xref ref-type="bibr" rid="bibr79-0884533612467824">79</xref>, <xref ref-type="bibr" rid="bibr80-0884533612467824">80</xref>, <xref ref-type="bibr" rid="bibr82-0884533612467824">82</xref>, <xref ref-type="bibr" rid="bibr85-0884533612467824">85</xref>, <xref ref-type="bibr" rid="bibr91-0884533612467824">91</xref>, <xref ref-type="bibr" rid="bibr101-0884533612467824">101</xref></sup>.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533612467824">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen-Lahav</surname><given-names>M</given-names></name>
<name><surname>Douvdevani</surname><given-names>A</given-names></name>
<name><surname>Chaimovitz</surname><given-names>C</given-names></name>
<name><surname>Shany</surname><given-names>S</given-names></name>
</person-group>. <article-title>The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2007</year>;<volume>103</volume>(<issue>3-5</issue>):<fpage>558</fpage>–<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr2-0884533612467824">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boucher</surname><given-names>BJ</given-names></name>
</person-group>. <article-title>Vitamin D insufficiency and diabetes risks</article-title>. <source>Curr Drug Targets</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr3-0884533612467824">
<label>3.</label>
<citation citation-type="book"><collab>World Health Organization, International Agency for Research on Cancer (IARC)</collab>. <source>Vitamin D and Cancer</source>. Working Group Report 5. <volume>Vol 5</volume>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>World Health Organization, IARC</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr4-0884533612467824">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baeke</surname><given-names>F</given-names></name>
<name><surname>Takiishi</surname><given-names>T</given-names></name>
<name><surname>Korf</surname><given-names>H</given-names></name>
<name><surname>Gysemans</surname><given-names>C</given-names></name>
<name><surname>Mathieu</surname><given-names>C</given-names></name>
</person-group>. <article-title>Vitamin D: modulator of the immune system</article-title>. <source>Curr Opin Pharmacol</source>. <year>2010</year>;<volume>10</volume>(<issue>4</issue>):<fpage>482</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr5-0884533612467824">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reddy Vanga</surname><given-names>S</given-names></name>
<name><surname>Good</surname><given-names>M</given-names></name>
<name><surname>Howard</surname><given-names>PA</given-names></name>
<name><surname>Vacek</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Role of vitamin D in cardiovascular health</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>(<issue>6</issue>):<fpage>798</fpage>–<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr6-0884533612467824">
<label>6.</label>
<citation citation-type="journal"><collab>Vitamin D sales strong in 2010, supply costs rising</collab>. <source>Nutrition Business Journal</source>. <year>2011</year>;<volume>16</volume>:<fpage>137</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr7-0884533612467824">
<label>7.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Moshfegh</surname><given-names>A</given-names></name>
<name><surname>Goldman</surname><given-names>J</given-names></name>
<name><surname>Ahuja</surname><given-names>J</given-names></name>
<name><surname>Rhodes</surname><given-names>D</given-names></name>
<name><surname>LaComb</surname><given-names>R</given-names></name>
</person-group>. <source>What We Eat in America, NHANES 2005-2006: Usual Nutrient Intake From Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus and Magnesium</source>. <publisher-loc>Beltsville, MD</publisher-loc>: <publisher-name>US Department of Agriculture, Agricultural Research Service</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr8-0884533612467824">
<label>8.</label>
<citation citation-type="gov"><collab>Office of Dietary Supplements, National Institutes of Health</collab>. <article-title>Dietary supplement fact sheet: vitamin D</article-title>. <ext-link ext-link-type="uri" xlink:href="http://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional#h9">http://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional#h9</ext-link>. <access-date>Accessed November 17, 2011</access-date>.</citation>
</ref>
<ref id="bibr9-0884533612467824">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>HL</given-names></name>
</person-group>. <article-title>The 25-hydroxyvitamin D 1alpha-hydroxylase</article-title>. In: <person-group person-group-type="editor">
<name><surname>Feldman</surname><given-names>D</given-names></name>
<name><surname>Pike</surname><given-names>JW</given-names></name>
<name><surname>Gloriueux</surname><given-names>FH</given-names></name>
</person-group>, eds. <source>Vitamin D</source>. <volume>Vol 1</volume>. <edition>2nd ed.</edition> <publisher-loc>Boston</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <volume>2005</volume>:<fpage>69</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr10-0884533612467824">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norman</surname><given-names>AW</given-names></name>
<name><surname>Mizwicki</surname><given-names>MT</given-names></name>
<name><surname>Norman</surname><given-names>DP</given-names></name>
</person-group>. <article-title>Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model</article-title>. <source>Nat Rev Drug Discov</source>. <year>2004</year>;<volume>3</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr11-0884533612467824">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pascussi</surname><given-names>JM</given-names></name>
<name><surname>Gerbal-Chaloin</surname><given-names>S</given-names></name>
<name><surname>Drocourt</surname><given-names>L</given-names></name>
<name><surname>Maurel</surname><given-names>P</given-names></name>
<name><surname>Vilarem</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors</article-title>. <source>Biochim Biophys Acta</source>. <year>2003</year>;<volume>1619</volume>(<issue>3</issue>):<fpage>243</fpage>–<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr12-0884533612467824">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chatterjee</surname><given-names>B</given-names></name>
<name><surname>Echchgadda</surname><given-names>I</given-names></name>
<name><surname>Song</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1</article-title>. <source>Methods Enzymol</source>. <year>2005</year>;<volume>400</volume>:<fpage>165</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr13-0884533612467824">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fan</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>S</given-names></name>
<name><surname>Du</surname><given-names>Y</given-names></name>
<name><surname>Morrison</surname><given-names>J</given-names></name>
<name><surname>Shipman</surname><given-names>R</given-names></name>
<name><surname>Pang</surname><given-names>KS</given-names></name>
</person-group>. <article-title>Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2009</year>;<volume>330</volume>(<issue>2</issue>):<fpage>389</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr14-0884533612467824">
<label>14.</label>
<citation citation-type="book"><collab>Institute of Medicine</collab>. <source>Dietary Reference Intakes for Vitamin D and Calcium</source>. <volume>Vol 2010</volume>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Institute of Medicine</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr15-0884533612467824">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name>
<name><surname>Giovannucci</surname><given-names>E</given-names></name>
<name><surname>Willett</surname><given-names>WC</given-names></name>
<name><surname>Dietrich</surname><given-names>T</given-names></name>
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
</person-group>. <article-title>Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes</article-title>. <source>Am J Clin Nutr</source>. <year>2006</year>;<volume>84</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr16-0884533612467824">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieth</surname><given-names>R</given-names></name>
<name><surname>Bischoff-Ferrari</surname><given-names>H</given-names></name>
<name><surname>Boucher</surname><given-names>BJ</given-names></name>
<etal/></person-group>. <article-title>The urgent need to recommend an intake of vitamin D that is effective</article-title>. <source>Am J Clin Nutr</source>. <year>2007</year>;<volume>85</volume>(<issue>3</issue>):<fpage>649</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr17-0884533612467824">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollis</surname><given-names>BW</given-names></name>
</person-group>. <article-title>Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D</article-title>. <source>J Nutr</source>. <year>2005</year>;<volume>135</volume>(<issue>2</issue>):<fpage>317</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr18-0884533612467824">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wortsman</surname><given-names>J</given-names></name>
<name><surname>Matsuoka</surname><given-names>LY</given-names></name>
<name><surname>Chen</surname><given-names>TC</given-names></name>
<name><surname>Lu</surname><given-names>Z</given-names></name>
<name><surname>Holick</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Decreased bioavailability of vitamin D in obesity</article-title>. <source>Am J Clin Nutr</source>. <year>2000</year>;<volume>72</volume>(<issue>3</issue>):<fpage>690</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr19-0884533612467824">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Webb</surname><given-names>AR</given-names></name>
<name><surname>Kline</surname><given-names>L</given-names></name>
<name><surname>Holick</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1988</year>;<volume>67</volume>(<issue>2</issue>):<fpage>373</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr20-0884533612467824">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
<name><surname>Harris</surname><given-names>SS</given-names></name>
<name><surname>Dallal</surname><given-names>GE</given-names></name>
</person-group>. <article-title>Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women</article-title>. <source>Am J Clin Nutr</source>. <year>1997</year>;<volume>65</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr21-0884533612467824">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
<name><surname>Heaney</surname><given-names>RP</given-names></name>
<name><surname>Holick</surname><given-names>MF</given-names></name>
<name><surname>Lips</surname><given-names>P</given-names></name>
<name><surname>Meunier</surname><given-names>PJ</given-names></name>
<name><surname>Vieth</surname><given-names>R</given-names></name>
</person-group>. <article-title>Estimates of optimal vitamin D status</article-title>. <source>Osteoporos Int</source>. <year>2005</year>;<volume>16</volume>(<issue>7</issue>):<fpage>713</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr22-0884533612467824">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luo</surname><given-names>G</given-names></name>
<name><surname>Guenthner</surname><given-names>T</given-names></name>
<name><surname>Gan</surname><given-names>LS</given-names></name>
<name><surname>Humphreys</surname><given-names>WG</given-names></name>
</person-group>. <article-title>CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development</article-title>. <source>Curr Drug Metab</source>. <year>2004</year>;<volume>5</volume>(<issue>6</issue>):<fpage>483</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr23-0884533612467824">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>SF</given-names></name>
</person-group>. <article-title>Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4</article-title>. <source>Curr Drug Metab</source>. <year>2008</year>;<volume>9</volume>(<issue>4</issue>):<fpage>310</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr24-0884533612467824">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watkins</surname><given-names>PB</given-names></name>
<name><surname>Wrighton</surname><given-names>SA</given-names></name>
<name><surname>Schuetz</surname><given-names>EG</given-names></name>
<name><surname>Molowa</surname><given-names>DT</given-names></name>
<name><surname>Guzelian</surname><given-names>PS</given-names></name>
</person-group>. <article-title>Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man</article-title>. <source>J Clin Invest</source>. <year>1987</year>;<volume>80</volume>(<issue>4</issue>):<fpage>1029</fpage>–<lpage>1036</lpage>.</citation>
</ref>
<ref id="bibr25-0884533612467824">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kolars</surname><given-names>JC</given-names></name>
<name><surname>Schmiedlin-Ren</surname><given-names>P</given-names></name>
<name><surname>Schuetz</surname><given-names>JD</given-names></name>
<name><surname>Fang</surname><given-names>C</given-names></name>
<name><surname>Watkins</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes</article-title>. <source>J Clin Invest</source>. <year>1992</year>;<volume>90</volume>(<issue>5</issue>):<fpage>1871</fpage>–<lpage>1878</lpage>.</citation>
</ref>
<ref id="bibr26-0884533612467824">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thummel</surname><given-names>KE</given-names></name>
<name><surname>Brimer</surname><given-names>C</given-names></name>
<name><surname>Yasuda</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3</article-title>. <source>Mol Pharmacol</source>. <year>2001</year>;<volume>60</volume>(<issue>6</issue>):<fpage>1399</fpage>–<lpage>1406</lpage>.</citation>
</ref>
<ref id="bibr27-0884533612467824">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindh</surname><given-names>JD</given-names></name>
<name><surname>Andersson</surname><given-names>ML</given-names></name>
<name><surname>Eliasson</surname><given-names>E</given-names></name>
<name><surname>Bjorkhem-Bergman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Seasonal variation in blood drug concentrations and a potential relationship to vitamin D</article-title>. <source>Drug Metab Dispos</source>. <year>2011</year>;<volume>39</volume>(<issue>5</issue>):<fpage>933</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr28-0884533612467824">
<label>28.</label>
<citation citation-type="book"><collab>American Dietetic Association</collab>. <source>Evidence Analysis Manual: Steps in the ADA Evidence Analysis Process</source>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>American Dietetic Association</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr29-0884533612467824">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoogwerf</surname><given-names>BJ</given-names></name>
<name><surname>Hibbard</surname><given-names>DM</given-names></name>
<name><surname>Hunninghake</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia</article-title>. <source>J Lab Clin Med</source>. <year>1992</year>; <volume>119</volume>(<issue>4</issue>):<fpage>407</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr30-0884533612467824">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tonstad</surname><given-names>S</given-names></name>
<name><surname>Knudtzon</surname><given-names>J</given-names></name>
<name><surname>Sivertsen</surname><given-names>M</given-names></name>
<name><surname>Refsum</surname><given-names>H</given-names></name>
<name><surname>Ose</surname><given-names>L</given-names></name>
</person-group>. <article-title>Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia</article-title>. <source>J Pediatr</source>. <year>1996</year>;<volume>129</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr31-0884533612467824">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>F</given-names></name>
<name><surname>Corder</surname><given-names>CN</given-names></name>
<name><surname>Epstein</surname><given-names>S</given-names></name>
<name><surname>Barbi</surname><given-names>G</given-names></name>
<name><surname>Thomas</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites</article-title>. <source>Clin Ther</source>. <year>1990</year>;<volume>12</volume>(<issue>5</issue>):<fpage>427</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr32-0884533612467824">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsang</surname><given-names>RC</given-names></name>
<name><surname>Roginsky</surname><given-names>MS</given-names></name>
<name><surname>Mellies</surname><given-names>MJ</given-names></name>
<name><surname>Glueck</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin</article-title>. <source>Pediatr Res</source>. <year>1978</year>;<volume>12</volume>(<issue>10</issue>):<fpage>980</fpage>–<lpage>982</lpage>.</citation>
</ref>
<ref id="bibr33-0884533612467824">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>KB</given-names></name>
<name><surname>Goldstein</surname><given-names>PD</given-names></name>
<name><surname>Witztum</surname><given-names>JL</given-names></name>
<name><surname>Schonfeld</surname><given-names>G</given-names></name>
</person-group>. <article-title>Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol</article-title>. <source>Pediatrics</source>. <year>1980</year>;<volume>65</volume>(<issue>2</issue>):<fpage>243</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr34-0884533612467824">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reitsma</surname><given-names>JB</given-names></name>
<name><surname>Castro Cabezas</surname><given-names>M</given-names></name>
<name><surname>de Bruin</surname><given-names>TW</given-names></name>
<name><surname>Erkelens</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor</article-title>. <source>Metab Clin Exp</source>. <year>1994</year>;<volume>43</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr35-0884533612467824">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guerciolini</surname><given-names>R</given-names></name>
</person-group>. <article-title>Mode of action of orlistat</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>1997</year>;<volume>21</volume>(<supplement>suppl 3</supplement>):<fpage>S12</fpage>.</citation>
</ref>
<ref id="bibr36-0884533612467824">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotfredsen</surname><given-names>A</given-names></name>
<name><surname>Westergren Hendel</surname><given-names>H</given-names></name>
<name><surname>Andersen</surname><given-names>T</given-names></name>
</person-group>. <article-title>Influence of orlistat on bone turnover and body composition</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>2001</year>;<volume>25</volume>(<issue>8</issue>):<fpage>1154</fpage>–<lpage>1160</lpage>.</citation>
</ref>
<ref id="bibr37-0884533612467824">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>James</surname><given-names>WP</given-names></name>
<name><surname>Avenell</surname><given-names>A</given-names></name>
<name><surname>Broom</surname><given-names>J</given-names></name>
<name><surname>Whitehead</surname><given-names>J</given-names></name>
</person-group>. <article-title>A one-year trial to assess the value of orlistat in the management of obesity</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>1997</year>;<volume>21</volume>(<supplement>suppl 3</supplement>):<fpage>S24</fpage>–<lpage>S30</lpage>.</citation>
</ref>
<ref id="bibr38-0884533612467824">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDuffie</surname><given-names>JR</given-names></name>
<name><surname>Calis</surname><given-names>KA</given-names></name>
<name><surname>Booth</surname><given-names>SL</given-names></name>
<name><surname>Uwaifo</surname><given-names>GI</given-names></name>
<name><surname>Yanovski</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Effects of orlistat on fat-soluble vitamins in obese adolescents</article-title>. <source>Pharmacotherapy</source>. <year>2002</year>;<volume>22</volume>(<issue>7</issue>):<fpage>814</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr39-0884533612467824">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Istvan</surname><given-names>ES</given-names></name>
<name><surname>Deisenhofer</surname><given-names>J</given-names></name>
</person-group>. <article-title>Structural mechanism for statin inhibition of HMG-CoA reductase</article-title>. <source>Science</source>. <year>2001</year>;<volume>292</volume>(<issue>5519</issue>):<fpage>1160</fpage>–<lpage>1164</lpage>.</citation>
</ref>
<ref id="bibr40-0884533612467824">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dobs</surname><given-names>AS</given-names></name>
<name><surname>Levine</surname><given-names>MA</given-names></name>
<name><surname>Margolis</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man</article-title>. <source>Metabolism</source>. <year>1991</year>;<volume>40</volume>(<issue>5</issue>):<fpage>524</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr41-0884533612467824">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montagnani</surname><given-names>M</given-names></name>
<name><surname>Lore</surname><given-names>F</given-names></name>
<name><surname>Di Cairano</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Effects of pravastatin treatment on vitamin D metabolites</article-title>. <source>Clin Ther</source>. <year>1994</year>;<volume>16</volume>(<issue>5</issue>):<fpage>824</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr42-0884533612467824">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vaughan</surname><given-names>CJ</given-names></name>
<name><surname>Gotto</surname><given-names>AM</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Update on statins: 2003</article-title>. <source>Circulation</source>. <year>2004</year>; <volume>110</volume>(<issue>7</issue>):<fpage>886</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr43-0884533612467824">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>D</given-names></name>
<name><surname>Feely</surname><given-names>J</given-names></name>
</person-group>. <article-title>Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors</article-title>. <source>Clin Pharmacokinet</source>. <year>2002</year>;<volume>41</volume>(<issue>5</issue>):<fpage>343</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr44-0884533612467824">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neuvonen</surname><given-names>PJ</given-names></name>
<name><surname>Niemi</surname><given-names>M</given-names></name>
<name><surname>Backman</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Drug interactions with lipid- lowering drugs: mechanisms and clinical relevance</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>80</volume>(<issue>6</issue>):<fpage>565</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr45-0884533612467824">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence</article-title>. <source>Clin Pharmacol Ther</source>. <year>2009</year>;<volume>85</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr46-0884533612467824">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perez-Castrillon</surname><given-names>JL</given-names></name>
<name><surname>Vega</surname><given-names>G</given-names></name>
<name><surname>Abad</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>(<issue>7</issue>):<fpage>903</fpage>–<lpage>905</lpage>.</citation>
</ref>
<ref id="bibr47-0884533612467824">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perez-Castrillon</surname><given-names>JL</given-names></name>
<name><surname>Abad</surname><given-names>L</given-names></name>
<name><surname>Vega</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2008</year>;<volume>12</volume>(<issue>2</issue>):<fpage>83</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr48-0884533612467824">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aloia</surname><given-names>JF</given-names></name>
<name><surname>Li-Ng</surname><given-names>M</given-names></name>
<name><surname>Pollack</surname><given-names>S</given-names></name>
</person-group>. <article-title>Statins and vitamin D</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>100</volume>(<issue>8</issue>):<fpage>1329</fpage>.</citation>
</ref>
<ref id="bibr49-0884533612467824">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gauvain</surname><given-names>S</given-names></name>
</person-group>. <article-title>Calciferol in the treatment of tuberculous glands</article-title>. <source>Tubercle</source>. <year>1948</year>;<volume>29</volume>(<issue>11</issue>):<fpage>259</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr50-0884533612467824">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chocano Bedoya</surname><given-names>P</given-names></name>
<name><surname>Ronnenberg</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Vitamin D and tuberculosis</article-title>. <source>Nutr. Rev</source>. <year>2009</year>;<volume>67</volume>(<issue>5</issue>):<fpage>289</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr51-0884533612467824">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nnoaham</surname><given-names>KE</given-names></name>
<name><surname>Clarke</surname><given-names>A</given-names></name>
</person-group>. <article-title>Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis</article-title>. <source>Int J Epidemiol</source>. <year>2008</year>;<volume>37</volume>(<issue>1</issue>): <fpage>113</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr52-0884533612467824">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S</given-names></name>
<name><surname>Chan</surname><given-names>E</given-names></name>
<name><surname>Lim</surname><given-names>LY</given-names></name>
<etal/></person-group>. <article-title>Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4</article-title>. <source>Curr Drug Metab</source>. <year>2004</year>;<volume>5</volume>(<issue>5</issue>):<fpage>415</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr53-0884533612467824">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brodie</surname><given-names>MJ</given-names></name>
<name><surname>Boobis</surname><given-names>AR</given-names></name>
<name><surname>Dollery</surname><given-names>CT</given-names></name>
<etal/></person-group>. <article-title>Rifampicin and vitamin D metabolism</article-title>. <source>Clin Pharmacol Ther</source>. <year>1980</year>;<volume>27</volume>(<issue>6</issue>):<fpage>810</fpage>–<lpage>814</lpage>.</citation>
</ref>
<ref id="bibr54-0884533612467824">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brodie</surname><given-names>MJ</given-names></name>
<name><surname>Boobis</surname><given-names>AR</given-names></name>
<name><surname>Hillyard</surname><given-names>CJ</given-names></name>
<name><surname>Abeyasekera</surname><given-names>G</given-names></name>
<name><surname>MacIntyre</surname><given-names>I</given-names></name>
<name><surname>Park</surname><given-names>BK</given-names></name>
</person-group>. <article-title>Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity</article-title>. <source>Clin Pharmacol Ther</source>. <year>1981</year>;<volume>30</volume>(<issue>3</issue>):<fpage>363</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr55-0884533612467824">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brodie</surname><given-names>MJ</given-names></name>
<name><surname>Boobis</surname><given-names>AR</given-names></name>
<name><surname>Hillyard</surname><given-names>CJ</given-names></name>
<etal/></person-group>. <article-title>Effect of rifampicin and isoniazid on vitamin D metabolism</article-title>. <source>Clin Pharmacol Ther</source>. <year>1982</year>;<volume>32</volume>(<issue>4</issue>):<fpage>525</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr56-0884533612467824">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>PD</given-names></name>
<name><surname>Brown</surname><given-names>RC</given-names></name>
<name><surname>Church</surname><given-names>HA</given-names></name>
<name><surname>Woodhead</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The effect of anti-tuberculosis chemotherapy on vitamin D and calcium metabolism</article-title>. <source>Tubercle</source>. <year>1987</year>;<volume>68</volume>(<issue>4</issue>):<fpage>261</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr57-0884533612467824">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>SE</given-names></name>
<name><surname>Wardman</surname><given-names>AG</given-names></name>
<name><surname>Taylor</surname><given-names>GA</given-names></name>
<name><surname>Peacock</surname><given-names>M</given-names></name>
<name><surname>Cooke</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism</article-title>. <source>Tubercle</source>. <year>1985</year>;<volume>66</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr58-0884533612467824">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>ME</given-names></name>
<name><surname>Gonzalez</surname><given-names>J</given-names></name>
<name><surname>Sanchez-Cabezudo</surname><given-names>MJ</given-names></name>
<name><surname>Pena</surname><given-names>JM</given-names></name>
<name><surname>Vazquez</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Remission of hypercalciuria in patients with tuberculosis after treatment</article-title>. <source>Calcif Tissue Int</source>. <year>1996</year>;<volume>59</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr59-0884533612467824">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Egurbide</surname><given-names>MV</given-names></name>
<name><surname>Olivares</surname><given-names>N</given-names></name>
<name><surname>Martinez-Berriotxoa</surname><given-names>A</given-names></name>
<name><surname>Aguirre</surname><given-names>C</given-names></name>
</person-group>. <article-title>Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences</article-title>. <source>Rheumatology</source>. <year>2008</year>;<volume>47</volume>:<fpage>920</fpage>–<lpage>923</lpage>.</citation>
</ref>
<ref id="bibr60-0884533612467824">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>E</given-names></name>
</person-group>. <article-title>Clinically significant pharmacokinetic drug interactions between antiepileptic drugs</article-title>. <source>J Clin Pharm Ther</source>. <year>1999</year>;<volume>24</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr61-0884533612467824">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pascussi</surname><given-names>JM</given-names></name>
<name><surname>Robert</surname><given-names>A</given-names></name>
<name><surname>Nguyen</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Possible involvement of pregnane X receptor–enhanced CYP24 expression in drug-induced osteomalacia</article-title>. <source>J Clin Invest</source>. <year>2005</year>;<volume>115</volume>(<issue>1</issue>):<fpage>177</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr62-0884533612467824">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Hashizume</surname><given-names>T</given-names></name>
<name><surname>Shuhart</surname><given-names>MC</given-names></name>
<etal/></person-group>. <article-title>Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia</article-title>. <source>Mol Pharmacol</source>. <year>2006</year>;<volume>69</volume>(<issue>1</issue>):<fpage>56</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr63-0884533612467824">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morijiri</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>T</given-names></name>
</person-group>. <article-title>Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy</article-title>. <source>Arch Dis Child</source>. <year>1981</year>;<volume>56</volume>(<issue>6</issue>):<fpage>446</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr64-0884533612467824">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krause</surname><given-names>KH</given-names></name>
<name><surname>Berlit</surname><given-names>P</given-names></name>
<name><surname>Bonjour</surname><given-names>JP</given-names></name>
<name><surname>Schmidt-Gayk</surname><given-names>H</given-names></name>
<name><surname>Schellenberg</surname><given-names>B</given-names></name>
<name><surname>Gillen</surname><given-names>J</given-names></name>
</person-group>. <article-title>Vitamin status in patients on chronic anticonvulsant therapy</article-title>. <source>Int J Vitam Nutr Res</source>. <year>1982</year>;<volume>52</volume>(<issue>4</issue>):<fpage>375</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr65-0884533612467824">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gough</surname><given-names>H</given-names></name>
<name><surname>Bissesar</surname><given-names>A</given-names></name>
<name><surname>Goggin</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy</article-title>. <source>Ir J Med Sci</source>. <year>1986</year>;<volume>155</volume>(<issue>6</issue>):<fpage>181</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr66-0884533612467824">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gough</surname><given-names>H</given-names></name>
<name><surname>Goggin</surname><given-names>T</given-names></name>
<name><surname>Bissessar</surname><given-names>A</given-names></name>
<name><surname>Baker</surname><given-names>M</given-names></name>
<name><surname>Crowley</surname><given-names>M</given-names></name>
<name><surname>Callaghan</surname><given-names>N</given-names></name>
</person-group>. <article-title>A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy</article-title>. <source>Q J Med</source>. <year>1986</year>;<volume>59</volume>(<issue>230</issue>):<fpage>569</fpage>–<lpage>577</lpage>.</citation>
</ref>
<ref id="bibr67-0884533612467824">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nettekoven</surname><given-names>S</given-names></name>
<name><surname>Strohle</surname><given-names>A</given-names></name>
<name><surname>Trunz</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy</article-title>. <source>Eur J Pediatr</source>. <year>2008</year>;<volume>167</volume>(<issue>12</issue>):<fpage>1369</fpage>–<lpage>1377</lpage>.</citation>
</ref>
<ref id="bibr68-0884533612467824">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>TJ</given-names></name>
<name><surname>Hendin</surname><given-names>BA</given-names></name>
<name><surname>Scharp</surname><given-names>CR</given-names></name>
<name><surname>Haddad</surname><given-names>JG</given-names><suffix>Jr</suffix></name>
</person-group> <article-title>Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults</article-title>. <source>N Engl J Med</source>. <year>1972</year>;<volume>287</volume>(<issue>18</issue>):<fpage>900</fpage>–<lpage>904</lpage>.</citation>
</ref>
<ref id="bibr69-0884533612467824">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouillon</surname><given-names>R</given-names></name>
<name><surname>Reynaert</surname><given-names>J</given-names></name>
<name><surname>Claes</surname><given-names>JH</given-names></name>
<name><surname>Lissens</surname><given-names>W</given-names></name>
<name><surname>De Moor</surname><given-names>P</given-names></name>
</person-group>. <article-title>The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1975</year>;<volume>41</volume>(<issue>06</issue>): <fpage>1130</fpage>–<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr70-0884533612467824">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jubiz</surname><given-names>W</given-names></name>
<name><surname>Haussler</surname><given-names>MR</given-names></name>
<name><surname>McCain</surname><given-names>TA</given-names></name>
<name><surname>Tolman</surname><given-names>KG</given-names></name>
</person-group>. <article-title>Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1977</year>;<volume>44</volume>(<issue>4</issue>):<fpage>617</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr71-0884533612467824">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pylypchuk</surname><given-names>G</given-names></name>
<name><surname>Oreopoulos</surname><given-names>DG</given-names></name>
<name><surname>Wilson</surname><given-names>DR</given-names></name>
<etal/></person-group>. <article-title>Calcium metabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy</article-title>. <source>Can Med Assoc J</source>. <year>1978</year>;<volume>118</volume>(<issue>6</issue>):<fpage>635</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr72-0884533612467824">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weisman</surname><given-names>Y</given-names></name>
<name><surname>Andriola</surname><given-names>M</given-names></name>
<name><surname>Reiter</surname><given-names>E</given-names></name>
<name><surname>Gruskin</surname><given-names>A</given-names></name>
<name><surname>Root</surname><given-names>A</given-names></name>
</person-group>. <article-title>Serum concentrations of 25-hydroxyvitamin D in Florida children: effect of anticonvulsant drugs</article-title>. <source>South Med J</source>. <year>1979</year>;<volume>72</volume>(<issue>4</issue>):<fpage>400</fpage>–<lpage>401</lpage>, <fpage>408</fpage>.</citation>
</ref>
<ref id="bibr73-0884533612467824">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>CK</given-names></name>
<name><surname>Lund</surname><given-names>B</given-names></name>
<name><surname>Lund</surname><given-names>BJ</given-names></name>
<name><surname>Sorensen</surname><given-names>OH</given-names></name>
<name><surname>Nielsen</surname><given-names>HE</given-names></name>
<name><surname>Mosekilde</surname><given-names>L</given-names></name>
</person-group>. <article-title>Reduced 2,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D in epileptic patients receiving chronic combined anticonvulsant therapy</article-title>. <source>Metab Bone Dis Relat Res</source>. <year>1981</year>;<volume>3</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr74-0884533612467824">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoikka</surname><given-names>V</given-names></name>
<name><surname>Savolainen</surname><given-names>K</given-names></name>
<name><surname>Alhava</surname><given-names>EM</given-names></name>
<name><surname>Sivenius</surname><given-names>J</given-names></name>
<name><surname>Karjalainen</surname><given-names>P</given-names></name>
<name><surname>Repo</surname><given-names>A</given-names></name>
</person-group>. <article-title>Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy</article-title>. <source>Acta Neurol Scand</source>. <year>1981</year>;<volume>64</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr75-0884533612467824">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoikka</surname><given-names>V</given-names></name>
<name><surname>Savolainen</surname><given-names>K</given-names></name>
<name><surname>Karjalainen</surname><given-names>P</given-names></name>
<name><surname>Alhava</surname><given-names>EM</given-names></name>
<name><surname>Sivenius</surname><given-names>J</given-names></name>
</person-group>. <article-title>Treatment of osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy</article-title>. <source>Ann Clin Res</source>. <year>1982</year>;<volume>14</volume>(<issue>2</issue>):<fpage>72</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr76-0884533612467824">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keck</surname><given-names>E</given-names></name>
<name><surname>Gollnick</surname><given-names>B</given-names></name>
<name><surname>Reinhardt</surname><given-names>D</given-names></name>
<name><surname>Karch</surname><given-names>D</given-names></name>
<name><surname>Peerenboom</surname><given-names>H</given-names></name>
<name><surname>Kruskemper</surname><given-names>HL</given-names></name>
</person-group>. <article-title>Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs</article-title>. <source>Eur J Pediatr</source>. <year>1982</year>;<volume>139</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr77-0884533612467824">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lamberg-Allardt</surname><given-names>C</given-names></name>
<name><surname>Wilska</surname><given-names>M</given-names></name>
<name><surname>Saraste</surname><given-names>KL</given-names></name>
<name><surname>Gronlund</surname><given-names>T</given-names></name>
</person-group>. <article-title>Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment</article-title>. <source>Ann Nutr Metab</source>. <year>1990</year>;<volume>34</volume>(<issue>4</issue>):<fpage>216</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr78-0884533612467824">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Valimaki</surname><given-names>MJ</given-names></name>
<name><surname>Tiihonen</surname><given-names>M</given-names></name>
<name><surname>Laitinen</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs</article-title>. <source>J Bone Miner Res</source>. <year>1994</year>;<volume>9</volume>(<issue>5</issue>):<fpage>631</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr79-0884533612467824">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baer</surname><given-names>MT</given-names></name>
<name><surname>Kozlowski</surname><given-names>BW</given-names></name>
<name><surname>Blyler</surname><given-names>EM</given-names></name>
<name><surname>Trahms</surname><given-names>CM</given-names></name>
<name><surname>Taylor</surname><given-names>ML</given-names></name>
<name><surname>Hogan</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status</article-title>. <source>Am J Clin Nutr</source>. <year>1997</year>;<volume>65</volume>(<issue>4</issue>):<fpage>1042</fpage>–<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr80-0884533612467824">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Vitamin D levels in noninstitutionalized children with cerebral palsy</article-title>. <source>J Child Neurol</source>. <year>1997</year>;<volume>12</volume>(<issue>7</issue>):<fpage>443</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr81-0884533612467824">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Telci</surname><given-names>A</given-names></name>
<name><surname>Cakatay</surname><given-names>U</given-names></name>
<name><surname>Kurt</surname><given-names>BB</given-names></name>
<etal/></person-group>. <article-title>Changes in bone turnover and deoxypyridinoline levels in epileptic patients</article-title>. <source>Clin Chem Lab Med</source>. <year>2000</year>;<volume>38</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr82-0884533612467824">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filardi</surname><given-names>S</given-names></name>
<name><surname>Guerreiro</surname><given-names>CA</given-names></name>
<name><surname>Magna</surname><given-names>LA</given-names></name>
<name><surname>Marques Neto</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Bone mineral density, vitamin D and anticonvulsant therapy</article-title>. <source>Arq Neuropsiquiatr</source>. <year>2000</year>;<volume>58</volume>(<issue>3A</issue>):<fpage>616</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr83-0884533612467824">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mintzer</surname><given-names>S</given-names></name>
<name><surname>Boppana</surname><given-names>P</given-names></name>
<name><surname>Toguri</surname><given-names>J</given-names></name>
<name><surname>DeSantis</surname><given-names>A</given-names></name>
</person-group>. <article-title>Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine</article-title>. <source>Epilepsia</source>. <year>2006</year>;<volume>47</volume>(<issue>3</issue>):<fpage>510</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr84-0884533612467824">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stamp</surname><given-names>TC</given-names></name>
<name><surname>Round</surname><given-names>JM</given-names></name>
<name><surname>Rowe</surname><given-names>DJ</given-names></name>
<name><surname>Haddad</surname><given-names>JG</given-names></name>
</person-group>. <article-title>Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs</article-title>. <source>Br Med J</source>. <year>1972</year>;<volume>4</volume>(<issue>5831</issue>):<fpage>9</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr85-0884533612467824">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weisman</surname><given-names>Y</given-names></name>
<name><surname>Fattal</surname><given-names>A</given-names></name>
<name><surname>Eisenberg</surname><given-names>Z</given-names></name>
<name><surname>Harel</surname><given-names>S</given-names></name>
<name><surname>Spirer</surname><given-names>Z</given-names></name>
<name><surname>Harell</surname><given-names>A</given-names></name>
</person-group>. <article-title>Decreased serum 24,25-dehydroxy vitamin D concentrations in children receiving chronic anticonvulsant therapy</article-title>. <source>Br Med J</source>. <year>1979</year>;<volume>2</volume>(<issue>6189</issue>):<fpage>521</fpage>–<lpage>523</lpage>.</citation>
</ref>
<ref id="bibr86-0884533612467824">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tjellesen</surname><given-names>L</given-names></name>
<name><surname>Christiansen</surname><given-names>C</given-names></name>
</person-group>. <article-title>Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants</article-title>. <source>Acta Neurol Scand</source>. <year>1982</year>;<volume>66</volume>(<issue>3</issue>):<fpage>335</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr87-0884533612467824">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zerwekh</surname><given-names>JE</given-names></name>
<name><surname>Homan</surname><given-names>R</given-names></name>
<name><surname>Tindall</surname><given-names>R</given-names></name>
<name><surname>Pak</surname><given-names>CY</given-names></name>
</person-group>. <article-title>Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics</article-title>. <source>Ann Neurol</source>. <year>1982</year>;<volume>12</volume>(<issue>2</issue>):<fpage>184</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr88-0884533612467824">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davie</surname><given-names>MW</given-names></name>
<name><surname>Emberson</surname><given-names>CE</given-names></name>
<name><surname>Lawson</surname><given-names>DE</given-names></name>
<etal/></person-group>. <article-title>Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D</article-title>. <source>Q J Med</source>. <year>1983</year>;<volume>52</volume>(<issue>205</issue>):<fpage>79</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr89-0884533612467824">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoikka</surname><given-names>V</given-names></name>
<name><surname>Alhava</surname><given-names>EM</given-names></name>
<name><surname>Karjalainen</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Carbamazepine and bone mineral metabolism</article-title>. <source>Acta Neurol Scand</source>. <year>1984</year>;<volume>70</volume>(<issue>2</issue>):<fpage>77</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr90-0884533612467824">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajantie</surname><given-names>J</given-names></name>
<name><surname>Lamberg-Allardt</surname><given-names>C</given-names></name>
<name><surname>Wilska</surname><given-names>M</given-names></name>
</person-group>. <article-title>Does carbamazepine treatment lead to a need of extra vitamin D in some mentally retarded children?</article-title> <source>Acta Paediatr Scand</source>. <year>1984</year>;<volume>73</volume>(<issue>3</issue>):<fpage>325</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr91-0884533612467824">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>RS</given-names></name>
<name><surname>Bryce</surname><given-names>GF</given-names></name>
<name><surname>Sappington</surname><given-names>LJ</given-names></name>
<name><surname>King</surname><given-names>DW</given-names></name>
<name><surname>Gallagher</surname><given-names>BB</given-names></name>
</person-group>. <article-title>Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1984</year>; <volume>58</volume>(<issue>6</issue>):<fpage>1003</fpage>–<lpage>1009</lpage>.</citation>
</ref>
<ref id="bibr92-0884533612467824">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>  Williams</surname><given-names>C</given-names></name>
<name><surname>Netzloff</surname><given-names>M</given-names></name>
<name><surname>Folkerts</surname><given-names>L</given-names></name>
<name><surname>Vargas</surname><given-names>A</given-names></name>
<name><surname>Garnica</surname><given-names>A</given-names></name>
<name><surname>Frias</surname><given-names>J</given-names></name>
</person-group>. <article-title>Vitamin D metabolism and anticonvulsant therapy: effect of sunshine on incidence of osteomalacia</article-title>. <source>South Med J</source>. <year>1984</year>;<volume>77</volume>(<issue>7</issue>):<fpage>834</fpage>–<lpage>836</lpage>, <fpage>842</fpage>.</citation>
</ref>
<ref id="bibr93-0884533612467824">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishiyama</surname><given-names>S</given-names></name>
<name><surname>Kuwahara</surname><given-names>T</given-names></name>
<name><surname>Matsuda</surname><given-names>I</given-names></name>
</person-group>. <article-title>Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication</article-title>. <source>Eur J Pediatr</source>. <year>1986</year>; <volume>144</volume>(<issue>5</issue>):<fpage>457</fpage>–<lpage>463</lpage>.</citation>
</ref>
<ref id="bibr94-0884533612467824">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fogelman</surname><given-names>I</given-names></name>
<name><surname>Gray</surname><given-names>JM</given-names></name>
<name><surname>Gardner</surname><given-names>MD</given-names></name>
<etal/></person-group>. <article-title>Do anticonvulsant drugs commonly induce osteomalacia?</article-title> <source>Scott Med J</source>. <year>1982</year>;<volume>27</volume>(<issue>2</issue>):<fpage>136</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr95-0884533612467824">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname><given-names>CY</given-names></name>
<name><surname>Ronen</surname><given-names>GM</given-names></name>
<name><surname>Atkinson</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy</article-title>. <source>Epilepsia</source>. <year>2001</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1141</fpage>–<lpage>1147</lpage>.</citation>
</ref>
<ref id="bibr96-0884533612467824">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farhat</surname><given-names>G</given-names></name>
<name><surname>Yamout</surname><given-names>B</given-names></name>
<name><surname>Mikati</surname><given-names>MA</given-names></name>
<name><surname>Demirjian</surname><given-names>S</given-names></name>
<name><surname>Sawaya</surname><given-names>R</given-names></name>
<name><surname>El-Hajj Fuleihan</surname><given-names>G</given-names></name>
</person-group>. <article-title>Effect of antiepileptic drugs on bone density in ambulatory patients</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>58</volume>(<issue>9</issue>):<fpage>1348</fpage>–<lpage>1353</lpage>.</citation>
</ref>
<ref id="bibr97-0884533612467824">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcus</surname><given-names>JC</given-names></name>
<name><surname>Pettifor</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Folate and mineral metabolism in poorly nourished epileptic children</article-title>. <source>Arch Neurol</source>. <year>1980</year>;<volume>37</volume>(<issue>12</issue>):<fpage>772</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr98-0884533612467824">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>K</given-names></name>
<name><surname>Ikeda</surname><given-names>H</given-names></name>
</person-group>. <article-title>High 1,25-dihydroxyvitamin D and low 25-hydroxyvitamin D concentrations in plasma in patients receiving antiepileptic drugs</article-title>. <source>Jpn J Psychiatry Neurol</source>. <year>1986</year>;<volume>40</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr99-0884533612467824">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winnacker</surname><given-names>JL</given-names></name>
<name><surname>Yeager</surname><given-names>H</given-names></name>
<name><surname>Saunders</surname><given-names>JA</given-names></name>
<name><surname>Russell</surname><given-names>B</given-names></name>
<name><surname>Anast</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Rickets in children receiving anticonvulsant drugs: biochemical and hormonal markers</article-title>. <source>Am J Dis Child</source>. <year>1977</year>;<volume>131</volume>(<issue>3</issue>):<fpage>286</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr100-0884533612467824">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markestad</surname><given-names>T</given-names></name>
<name><surname>Ulstein</surname><given-names>M</given-names></name>
<name><surname>Strandjord</surname><given-names>RE</given-names></name>
<name><surname>Aksnes</surname><given-names>L</given-names></name>
<name><surname>Aarskog</surname><given-names>D</given-names></name>
</person-group>. <article-title>Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood</article-title>. <source>Am J Obstet Gynecol</source>. <year>1984</year>;<volume>150</volume>(<issue>3</issue>):<fpage>254</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr101-0884533612467824">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ala-Houhala</surname><given-names>M</given-names></name>
<name><surname>Korpela</surname><given-names>R</given-names></name>
<name><surname>Koivikko</surname><given-names>M</given-names></name>
<name><surname>Koskinen</surname><given-names>T</given-names></name>
<name><surname>Koskinen</surname><given-names>M</given-names></name>
<name><surname>Koivula</surname><given-names>T</given-names></name>
</person-group>. <article-title>Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children</article-title>. <source>Neuropediatrics</source>. <year>1986</year>;<volume>17</volume>(<issue>4</issue>):<fpage>212</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr102-0884533612467824">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riancho</surname><given-names>JA</given-names></name>
<name><surname>del Arco</surname><given-names>C</given-names></name>
<name><surname>Arteaga</surname><given-names>R</given-names></name>
<name><surname>Herranz</surname><given-names>JL</given-names></name>
<name><surname>Albajar</surname><given-names>M</given-names></name>
<name><surname>Macias</surname><given-names>JG</given-names></name>
</person-group>. <article-title>Influence of solar irradiation on vitamin D levels in children on anticonvulsant drugs</article-title>. <source>Acta Neurol Scand</source>. <year>1989</year>;<volume>79</volume>(<issue>4</issue>):<fpage>296</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr103-0884533612467824">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicolaidou</surname><given-names>P</given-names></name>
<name><surname>Georgouli</surname><given-names>H</given-names></name>
<name><surname>Kotsalis</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study</article-title>. <source>J Child Neurol</source>. <year>2006</year>;<volume>21</volume>(<issue>3</issue>):<fpage>205</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr104-0884533612467824">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bramswig</surname><given-names>S</given-names></name>
<name><surname>Zittermann</surname><given-names>A</given-names></name>
<name><surname>Berthold</surname><given-names>HK</given-names></name>
</person-group>. <article-title>Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults</article-title>. <source>Calcif Tissue Int</source>. <year>2003</year>;<volume>73</volume>(<issue>4</issue>):<fpage>356</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr105-0884533612467824">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergqvist</surname><given-names>AG</given-names></name>
<name><surname>Schall</surname><given-names>JI</given-names></name>
<name><surname>Stallings</surname><given-names>VA</given-names></name>
</person-group>. <article-title>Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet</article-title>. <source>Epilepsia</source>. <year>2007</year>;<volume>48</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr106-0884533612467824">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pack</surname><given-names>AM</given-names></name>
<name><surname>Morrell</surname><given-names>MJ</given-names></name>
<name><surname>Randall</surname><given-names>A</given-names></name>
<name><surname>McMahon</surname><given-names>DJ</given-names></name>
<name><surname>Shane</surname><given-names>E</given-names></name>
</person-group>. <article-title>Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>70</volume>(<issue>18</issue>):<fpage>1586</fpage>–<lpage>1593</lpage>.</citation>
</ref>
<ref id="bibr107-0884533612467824">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SH</given-names></name>
<name><surname>Lee</surname><given-names>JW</given-names></name>
<name><surname>Choi</surname><given-names>KG</given-names></name>
<name><surname>Chung</surname><given-names>HW</given-names></name>
<name><surname>Lee</surname><given-names>HW</given-names></name>
</person-group>. <article-title>A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy</article-title>. <source>Epilepsy Behav</source>. <year>2007</year>;<volume>10</volume>(<issue>2</issue>):<fpage>291</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr108-0884533612467824">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cansu</surname><given-names>A</given-names></name>
<name><surname>Yesilkaya</surname><given-names>E</given-names></name>
<name><surname>Serdaroglu</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Evaluation of bone turnover in epileptic children using oxcarbazepine</article-title>. <source>Pediatr Neurol</source>. <year>2008</year>;<volume>39</volume>(<issue>4</issue>): <fpage>266</fpage>–<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr109-0884533612467824">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoikka</surname><given-names>V</given-names></name>
<name><surname>Savolainen</surname><given-names>K</given-names></name>
<name><surname>Alhava</surname><given-names>EM</given-names></name>
<name><surname>Sivenius</surname><given-names>J</given-names></name>
<name><surname>Karjalainen</surname><given-names>P</given-names></name>
<name><surname>Parvianinen</surname><given-names>M</given-names></name>
</person-group>. <article-title>Anticonvulsant osteomalacia in epileptic outpatients</article-title>. <source>Ann Clin Res</source>. <year>1982</year>;<volume>14</volume>(<issue>3</issue>):<fpage>129</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr110-0884533612467824">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rickers</surname><given-names>H</given-names></name>
<name><surname>Deding</surname><given-names>A</given-names></name>
<name><surname>Christiansen</surname><given-names>C</given-names></name>
<name><surname>Rodbro</surname><given-names>P</given-names></name>
<name><surname>Naestoft</surname><given-names>J</given-names></name>
</person-group>. <article-title>Corticosteroid-induced osteopenia and vitamin D metabolism: effect of vitamin D2, calcium phosphate and sodium fluoride administration</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1982</year>;<volume>16</volume>(<issue>4</issue>):<fpage>409</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr111-0884533612467824">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zerwekh</surname><given-names>JE</given-names></name>
<name><surname>Emkey</surname><given-names>RD</given-names></name>
<name><surname>Harris</surname><given-names>ED</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism</article-title>. <source>Arthritis Rheum</source>. <year>1984</year>;<volume>27</volume>(<issue>9</issue>):<fpage>1050</fpage>–<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr112-0884533612467824">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>TJ</given-names></name>
<name><surname>Halstead</surname><given-names>LR</given-names></name>
<name><surname>Baran</surname><given-names>DT</given-names></name>
</person-group>. <article-title>Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1981</year>;<volume>52</volume>(<issue>1</issue>):<fpage>111</fpage>–<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr113-0884533612467824">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prummel</surname><given-names>MF</given-names></name>
<name><surname>Wiersinga</surname><given-names>WM</given-names></name>
<name><surname>Lips</surname><given-names>P</given-names></name>
<name><surname>Sanders</surname><given-names>GT</given-names></name>
<name><surname>Sauerwein</surname><given-names>HP</given-names></name>
</person-group>. <article-title>The course of biochemical parameters of bone turnover during treatment with corticosteroids</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1991</year>;<volume>72</volume>(<issue>2</issue>):<fpage>382</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr114-0884533612467824">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lems</surname><given-names>WF</given-names></name>
<name><surname>Jacobs</surname><given-names>JW</given-names></name>
<name><surname>Van Rijn</surname><given-names>HJ</given-names></name>
<name><surname>Bijlsma</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers</article-title>. <source>Clin Rheumatol</source>. <year>1995</year>;<volume>14</volume>(<issue>4</issue>):<fpage>420</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr115-0884533612467824">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halton</surname><given-names>JM</given-names></name>
<name><surname>Atkinson</surname><given-names>SA</given-names></name>
<name><surname>Fraher</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia</article-title>. <source>J Bone Miner Res</source>. <year>1996</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1774</fpage>–<lpage>1783</lpage>.</citation>
</ref>
<ref id="bibr116-0884533612467824">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>TJ</given-names></name>
<name><surname>Halstead</surname><given-names>LR</given-names></name>
<name><surname>Haddad</surname><given-names>JG</given-names><suffix>Jr</suffix></name>
</person-group> <article-title>Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy</article-title>. <source>J Lab Clin Med</source>. <year>1977</year>;<volume>90</volume>(<issue>2</issue>):<fpage>399</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr117-0884533612467824">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>RG</given-names></name>
<name><surname>Arnaud</surname><given-names>SB</given-names></name>
<name><surname>Gallagher</surname><given-names>JC</given-names></name>
<name><surname>Deluca</surname><given-names>HF</given-names></name>
<name><surname>Riggs</surname><given-names>BL</given-names></name>
</person-group>. <article-title>Intestinal calcium absorption in exogenous hypercortisonism: role of 25-hydroxyvitamin D and corticosteroid dose</article-title>. <source>J Clin Invest</source>. <year>1977</year>;<volume>60</volume>(<issue>1</issue>):<fpage>253</fpage>–<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr118-0884533612467824">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lund</surname><given-names>B</given-names></name>
<name><surname>Storm</surname><given-names>TL</given-names></name>
<name><surname>Melsen</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment</article-title>. <source>Clin Rheumatol</source>. <year>1985</year>;<volume>4</volume>(<issue>2</issue>): <fpage>143</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr119-0884533612467824">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bikle</surname><given-names>DD</given-names></name>
<name><surname>Halloran</surname><given-names>B</given-names></name>
<name><surname>Fong</surname><given-names>L</given-names></name>
<name><surname>Steinbach</surname><given-names>L</given-names></name>
<name><surname>Shellito</surname><given-names>J</given-names></name>
</person-group>. <article-title>Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1993</year>; <volume>76</volume>(<issue>2</issue>):<fpage>456</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr120-0884533612467824">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wetzsteon</surname><given-names>RJ</given-names></name>
<name><surname>Shults</surname><given-names>J</given-names></name>
<name><surname>Zemel</surname><given-names>BS</given-names></name>
<etal/></person-group>. <article-title>Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome</article-title>. <source>J Bone Miner Res</source>. <year>2009</year>;<volume>24</volume>(<issue>3</issue>):<fpage>503</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr121-0884533612467824">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolthers</surname><given-names>OD</given-names></name>
<name><surname>Riis</surname><given-names>BJ</given-names></name>
<name><surname>Pedersen</surname><given-names>S</given-names></name>
</person-group>. <article-title>Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide</article-title>. <source>Pediatr Pulmonol</source>. <year>1993</year>;<volume>16</volume>(<issue>6</issue>):<fpage>341</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr122-0884533612467824">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bijlsma</surname><given-names>JW</given-names></name>
<name><surname>Duursma</surname><given-names>SA</given-names></name>
<name><surname>Huber-Bruning</surname><given-names>O</given-names></name>
</person-group>. <article-title>Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>. <year>1986</year>;<volume>45</volume>(<issue>9</issue>):<fpage>757</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr123-0884533612467824">
<label>123.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slovik</surname><given-names>DM</given-names></name>
<name><surname>Neer</surname><given-names>RM</given-names></name>
<name><surname>Ohman</surname><given-names>JL</given-names></name>
<etal/></person-group>. <article-title>Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients</article-title>. <source>Clin Endocrinol</source>. <year>1980</year>;<volume>12</volume>(<issue>3</issue>):<fpage>243</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr124-0884533612467824">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Als</surname><given-names>OS</given-names></name>
<name><surname>Riis</surname><given-names>B</given-names></name>
<name><surname>Christiansen</surname><given-names>C</given-names></name>
</person-group>. <article-title>Serum concentration of vitamin D metabolites in rheumatoid arthritis</article-title>. <source>Clin Rheumatol</source>. <year>1987</year>;<volume>6</volume>(<issue>2</issue>):<fpage>238</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr125-0884533612467824">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>von Scheven</surname><given-names>E</given-names></name>
<name><surname>Gordon</surname><given-names>CM</given-names></name>
<name><surname>Wypij</surname><given-names>D</given-names></name>
<name><surname>Wertz</surname><given-names>M</given-names></name>
<name><surname>Gallagher</surname><given-names>KT</given-names></name>
<name><surname>Bachrach</surname><given-names>L</given-names></name>
</person-group>. <article-title>Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study</article-title>. <source>J Pediatr Endocrinol Metab</source>. <year>2006</year>;<volume>19</volume>(<issue>6</issue>): <fpage>821</fpage>–<lpage>830</lpage>.</citation>
</ref>
<ref id="bibr126-0884533612467824">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sentongo</surname><given-names>TA</given-names></name>
<name><surname>Semaeo</surname><given-names>EJ</given-names></name>
<name><surname>Stettler</surname><given-names>N</given-names></name>
<name><surname>Piccoli</surname><given-names>DA</given-names></name>
<name><surname>Stallings</surname><given-names>VA</given-names></name>
<name><surname>Zemel</surname><given-names>BS</given-names></name>
</person-group>. <article-title>Vitamin D status in children, adolescents, and young adults with Crohn disease</article-title>. <source>Am J Clin Nutr</source>. <year>2002</year>;<volume>76</volume>(<issue>5</issue>):<fpage>1077</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr127-0884533612467824">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohran</surname><given-names>VC</given-names></name>
<name><surname>Griffiths</surname><given-names>M</given-names></name>
<name><surname>Heubi</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Bone mineral density in children exposed to chronic glucocorticoid therapy</article-title>. <source>Clin Pediatr</source>. <year>2008</year>;<volume>47</volume>(<issue>5</issue>): <fpage>469</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr128-0884533612467824">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santiago</surname><given-names>RA</given-names></name>
<name><surname>Silva</surname><given-names>CA</given-names></name>
<name><surname>Caparbo</surname><given-names>VF</given-names></name>
<name><surname>Sallum</surname><given-names>AM</given-names></name>
<name><surname>Pereira</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use</article-title>. <source>Scand J Rheumatol</source>. <year>2008</year>;<volume>37</volume>(<issue>1</issue>): <fpage>40</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr129-0884533612467824">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Princen</surname><given-names>HM</given-names></name>
<name><surname>Meijer</surname><given-names>P</given-names></name>
<name><surname>Wolthers</surname><given-names>BG</given-names></name>
<name><surname>Vonk</surname><given-names>RJ</given-names></name>
<name><surname>Kuipers</surname><given-names>F</given-names></name>
</person-group>. <article-title>Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis</article-title>. <source>Biochem J</source>. <year>1991</year>;<volume>275</volume>(<issue>pt 2</issue>):<fpage>501</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr130-0884533612467824">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winegar</surname><given-names>DA</given-names></name>
<name><surname>Salisbury</surname><given-names>JA</given-names></name>
<name><surname>Sundseth</surname><given-names>SS</given-names></name>
<name><surname>Hawke</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells</article-title>. <source>J Lipid Res</source>. <year>1996</year>;<volume>37</volume>(<issue>1</issue>):<fpage>179</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr131-0884533612467824">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Souidi</surname><given-names>M</given-names></name>
<name><surname>Parquet</surname><given-names>M</given-names></name>
<name><surname>Ferezou</surname><given-names>J</given-names></name>
<name><surname>Lutton</surname><given-names>C</given-names></name>
</person-group>. <article-title>Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster</article-title>. <source>Life Sci</source>. <year>1999</year>;<volume>64</volume>(<issue>17</issue>): <fpage>1585</fpage>–<lpage>1593</lpage>.</citation>
</ref>
<ref id="bibr132-0884533612467824">
<label>132.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gueguen</surname><given-names>Y</given-names></name>
<name><surname>Ferrari</surname><given-names>L</given-names></name>
<name><surname>Souidi</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2007</year>;<volume>100</volume>(<issue>6</issue>):<fpage>392</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr133-0884533612467824">
<label>133.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grenet</surname><given-names>O</given-names></name>
<name><surname>Bobadilla</surname><given-names>M</given-names></name>
<name><surname>Chibout</surname><given-names>SD</given-names></name>
<name><surname>Steiner</surname><given-names>S</given-names></name>
</person-group>. <article-title>Evidence for the impairment of the vitamin D activation pathway by cyclosporine A</article-title>. <source>Biochem Pharmacol</source>. <year>2000</year>;<volume>59</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr134-0884533612467824">
<label>134.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reichel</surname><given-names>H</given-names></name>
<name><surname>Grussinger</surname><given-names>A</given-names></name>
<name><surname>Knehans</surname><given-names>A</given-names></name>
<name><surname>Kuhn</surname><given-names>K</given-names></name>
<name><surname>Schmidt-Gayk</surname><given-names>H</given-names></name>
<name><surname>Ritz</surname><given-names>E</given-names></name>
</person-group>. <article-title>Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis</article-title>. <source>Clin Investig</source>. <year>1992</year>;<volume>70</volume>(<issue>7</issue>):<fpage>595</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr135-0884533612467824">
<label>135.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Sevaux</surname><given-names>RG</given-names></name>
<name><surname>Hoitsma</surname><given-names>AJ</given-names></name>
<name><surname>van Hoof</surname><given-names>HJ</given-names></name>
<name><surname>Corstens</surname><given-names>FJ</given-names></name>
<name><surname>Wetzels</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Abnormal vitamin D metabolism and loss of bone mass after renal transplantation</article-title>. <source>Nephron Clin Pract</source>. <year>2003</year>;<volume>93</volume>(<issue>1</issue>):<fpage>C21</fpage>–<lpage>C28</lpage>.</citation>
</ref>
<ref id="bibr136-0884533612467824">
<label>136.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saha</surname><given-names>HH</given-names></name>
<name><surname>Salmela</surname><given-names>KT</given-names></name>
<name><surname>Ahonen</surname><given-names>PJ</given-names></name>
<etal/></person-group>. <article-title>Sequential changes in vitamin D and calcium metabolism after successful renal transplantation</article-title>. <source>Scand J Urol Nephrol</source>. <year>1994</year>;<volume>28</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr137-0884533612467824">
<label>137.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaw</surname><given-names>AJ</given-names></name>
<name><surname>Hayes</surname><given-names>ME</given-names></name>
<name><surname>Davies</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Cyclosporin A and vitamin D metabolism: studies in patients with psoriasis and in rats</article-title>. <source>Clin Sci</source>. <year>1994</year>;<volume>86</volume>(<issue>5</issue>):<fpage>627</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr138-0884533612467824">
<label>138.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>BD</given-names></name>
<name><surname>Davies</surname><given-names>M</given-names></name>
<name><surname>Mawer</surname><given-names>EB</given-names></name>
<name><surname>Chalmers</surname><given-names>RJ</given-names></name>
<name><surname>Testa</surname><given-names>HJ</given-names></name>
<name><surname>Ballardie</surname><given-names>FW</given-names></name>
</person-group>. <article-title>Interrelationship between serum concentrations of 1,25-dihydroxyvitamin D, parathyroid hormone and renal haemodynamics after low dose cyclosporin</article-title>. <source>Miner Electrolyte Metab</source>. <year>1994</year>;<volume>20</volume>(<issue>5</issue>):<fpage>250</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr139-0884533612467824">
<label>139.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Falkiewicz</surname><given-names>K</given-names></name>
<name><surname>Kaminska</surname><given-names>D</given-names></name>
<name><surname>Nahaczewska</surname><given-names>W</given-names></name>
<etal/></person-group>. <article-title>Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation</article-title>. <source>Transplant Proc</source>. <year>2006</year>;<volume>38</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr140-0884533612467824">
<label>140.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwasaki</surname><given-names>K</given-names></name>
</person-group>. <article-title>Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics</article-title>. <source>Drug Metab Pharmacokinet</source>. <year>2007</year>;<volume>22</volume>(<issue>5</issue>):<fpage>328</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr141-0884533612467824">
<label>141.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meijerman</surname><given-names>I</given-names></name>
<name><surname>Beijnen</surname><given-names>JH</given-names></name>
<name><surname>Schellens</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Herb-drug interactions in oncology: focus on mechanisms of induction</article-title>. <source>Oncologist</source>. <year>2006</year>;<volume>11</volume>(<issue>7</issue>):<fpage>742</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr142-0884533612467824">
<label>142.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kailajarvi</surname><given-names>ME</given-names></name>
<name><surname>Salminen</surname><given-names>EK</given-names></name>
<name><surname>Paija</surname><given-names>OM</given-names></name>
<name><surname>Virtanent</surname><given-names>AM</given-names></name>
<name><surname>Leino</surname><given-names>AE</given-names></name>
<name><surname>Irjala</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy</article-title>. <source>Anticancer Res</source>. <year>2004</year>;<volume>24</volume>(<issue>2C</issue>):<fpage>1271</fpage>–<lpage>1274</lpage>.</citation>
</ref>
<ref id="bibr143-0884533612467824">
<label>143.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Shimizu</surname><given-names>M</given-names></name>
<name><surname>Yamada</surname><given-names>S</given-names></name>
<name><surname>Ozaki</surname><given-names>Y</given-names></name>
<name><surname>Aso</surname><given-names>T</given-names></name>
</person-group>. <article-title>The effects of chemotherapy including cisplatin on vitamin D metabolism</article-title>. <source>Endocr J</source>. <year>1993</year>;<volume>40</volume>(<issue>6</issue>):<fpage>737</fpage>–<lpage>742</lpage>.</citation>
</ref>
<ref id="bibr144-0884533612467824">
<label>144.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fakih</surname><given-names>MG</given-names></name>
<name><surname>Trump</surname><given-names>DL</given-names></name>
<name><surname>Johnson</surname><given-names>CS</given-names></name>
<name><surname>Tian</surname><given-names>L</given-names></name>
<name><surname>Muindi</surname><given-names>J</given-names></name>
<name><surname>Sunga</surname><given-names>AY</given-names></name>
</person-group>. <article-title>Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer</article-title>. <source>Int J Colorectal Dis</source>. <year>2009</year>;<volume>24</volume>(<issue>2</issue>):<fpage>219</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr145-0884533612467824">
<label>145.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Flexner</surname><given-names>C</given-names></name>
</person-group>. <article-title>Antiretroviral agents and treatment of HIV infection</article-title>. In: <person-group person-group-type="editor">
<name><surname>Brunton</surname><given-names>LL</given-names></name>
<name><surname>Lazo</surname><given-names>JS</given-names></name>
<name><surname>Parker</surname><given-names>KL</given-names></name>
</person-group> eds. <source>Goodman &amp; Gilman’s The Pharmacological Basis of Therapeutics</source>. <edition>11th ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr146-0884533612467824">
<label>146.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>SF</given-names></name>
<name><surname>Xue</surname><given-names>CC</given-names></name>
<name><surname>Yu</surname><given-names>XQ</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
</person-group>. <article-title>Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring</article-title>. <source>Ther Drug Monit</source>. <year>2007</year>;<volume>29</volume>(<issue>6</issue>):<fpage>687</fpage>–<lpage>710</lpage>.</citation>
</ref>
<ref id="bibr147-0884533612467824">
<label>147.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cozzolino</surname><given-names>M</given-names></name>
<name><surname>Vidal</surname><given-names>M</given-names></name>
<name><surname>Arcidiacono</surname><given-names>MV</given-names></name>
<name><surname>Tebas</surname><given-names>P</given-names></name>
<name><surname>Yarasheski</surname><given-names>KE</given-names></name>
<name><surname>Dusso</surname><given-names>AS</given-names></name>
</person-group>. <article-title>HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D</article-title>. <source>AIDS</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>513</fpage>–<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr148-0884533612467824">
<label>148.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramayo</surname><given-names>E</given-names></name>
<name><surname>Gonzalez-Moreno</surname><given-names>MP</given-names></name>
<name><surname>Macias</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2005</year>;<volume>21</volume>(<issue>11</issue>):<fpage>915</fpage>–<lpage>921</lpage>.</citation>
</ref>
<ref id="bibr149-0884533612467824">
<label>149.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curtis</surname><given-names>JR</given-names></name>
<name><surname>Smith</surname><given-names>B</given-names></name>
<name><surname>Weaver</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2006</year>;<volume>22</volume>(<issue>2</issue>):<fpage>125</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr150-0884533612467824">
<label>150.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia Aparicio</surname><given-names>AM</given-names></name>
<name><surname>Munoz Fernandez</surname><given-names>S</given-names></name>
<name><surname>Gonzalez</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Abnormalities in the bone mineral metabolism in HIV-infected patients</article-title>. <source>Clin Rheumatol</source>. <year>2006</year>;<volume>25</volume>(<issue>4</issue>):<fpage>537</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr151-0884533612467824">
<label>151.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bengoa</surname><given-names>JM</given-names></name>
<name><surname>Bolt</surname><given-names>MJ</given-names></name>
<name><surname>Rosenberg</surname><given-names>IH</given-names></name>
</person-group>. <article-title>Hepatic vitamin D 25-hydroxylase inhibition by cimetidine and isoniazid</article-title>. <source>J Lab Clin Med</source>. <year>1984</year>;<volume>104</volume>(<issue>4</issue>): <fpage>546</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr152-0884533612467824">
<label>152.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wyatt</surname><given-names>CL</given-names></name>
<name><surname>Jensen</surname><given-names>LS</given-names></name>
<name><surname>Rowland</surname><given-names>GN</given-names></name>
</person-group>. <article-title>Effect of cimetidine on eggshell quality and plasma 25-hydroxycholecalciferol in laying hens</article-title>. <source>Poult Sci</source>. <year>1990</year>;<volume>69</volume>(<issue>11</issue>):<fpage>1892</fpage>–<lpage>1899</lpage>.</citation>
</ref>
<ref id="bibr153-0884533612467824">
<label>153.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Odes</surname><given-names>HS</given-names></name>
<name><surname>Fraser</surname><given-names>GM</given-names></name>
<name><surname>Krugliak</surname><given-names>P</given-names></name>
<name><surname>Lamprecht</surname><given-names>SA</given-names></name>
<name><surname>Shany</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effect of cimetidine on hepatic vitamin D metabolism in humans</article-title>. <source>Digestion</source>. <year>1990</year>;<volume>46</volume>(<issue>2</issue>):<fpage>61</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr154-0884533612467824">
<label>154.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richards</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine</article-title>. <source>J Clin Gastroenterol</source>. <year>1983</year>;<volume>5</volume>(<supplement>suppl 1</supplement>):<fpage>81</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr155-0884533612467824">
<label>155.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hathcock</surname><given-names>JN</given-names></name>
<name><surname>Shao</surname><given-names>A</given-names></name>
<name><surname>Vieth</surname><given-names>R</given-names></name>
<name><surname>Heaney</surname><given-names>R</given-names></name>
</person-group>. <article-title>Risk assessment for vitamin D</article-title>. <source>Am J Clin Nutr</source>. <year>2007</year>;<volume>85</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr156-0884533612467824">
<label>156.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parfitt</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism</article-title>. <source>N Engl J Med</source>. <year>1969</year>;<volume>281</volume>(<issue>2</issue>):<fpage>55</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr157-0884533612467824">
<label>157.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lichtwitz</surname><given-names>A</given-names></name>
<name><surname>Parlier</surname><given-names>R</given-names></name>
<name><surname>de</surname><given-names>S</given-names></name>
<name><surname>Hioco</surname><given-names>D</given-names></name>
<name><surname>Miravet</surname><given-names>L</given-names></name>
</person-group>. <article-title>The hypocalciuric effect of diuretic sulfonamides [in French]</article-title>. <source>Sem Med Prof Med Soc</source>. <year>1961</year>; <volume>37</volume>:<fpage>2350</fpage>–<lpage>2362</lpage>.</citation>
</ref>
<ref id="bibr158-0884533612467824">
<label>158.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torsti</surname><given-names>P</given-names></name>
<name><surname>Lamberg</surname><given-names>BA</given-names></name>
</person-group>. <article-title>The effect of a two-day treatment with chlorothiazide on the urinary excretion of calcium, phosphate and sodium in hyper- and hypocalcemia</article-title>. <source>Acta Med Scand</source>. <year>1964</year>;<volume>175</volume>(<supplement>suppl 412</supplement>):<fpage>181</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr159-0884533612467824">
<label>159.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>BA</given-names></name>
<name><surname>Nassim</surname><given-names>JR</given-names></name>
<name><surname>Collins</surname><given-names>J</given-names></name>
<name><surname>Hilb</surname><given-names>A</given-names></name>
</person-group>. <article-title>The effect of bendrofluazide on urine calcium excretion</article-title>. <source>Clin Sci</source>. <year>1964</year>;<volume>27</volume>:<fpage>457</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr160-0884533612467824">
<label>160.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drinka</surname><given-names>PJ</given-names></name>
<name><surname>Nolten</surname><given-names>WE</given-names></name>
</person-group>. <article-title>Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics</article-title>. <source>J Am Geriatr Soc</source>. <year>1984</year>;<volume>32</volume>(<issue>5</issue>):<fpage>405</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr161-0884533612467824">
<label>161.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crowe</surname><given-names>M</given-names></name>
<name><surname>Wollner</surname><given-names>L</given-names></name>
<name><surname>Griffiths</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Hypercalcaemia following vitamin D and thiazide therapy in the elderly</article-title>. <source>Practitioner</source>. <year>1984</year>;<volume>228</volume>(<issue>1389</issue>): <fpage>312</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr162-0884533612467824">
<label>162.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riis</surname><given-names>B</given-names></name>
<name><surname>Christiansen</surname><given-names>C</given-names></name>
</person-group>. <article-title>Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause</article-title>. <source>Metab Clin Exp</source>. <year>1985</year>;<volume>34</volume>(<issue>5</issue>):<fpage>421</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr163-0884533612467824">
<label>163.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemann</surname><given-names>J</given-names><suffix>Jr</suffix></name>
<name><surname>Gray</surname><given-names>RW</given-names></name>
<name><surname>Maierhofer</surname><given-names>WJ</given-names></name>
<name><surname>Cheung</surname><given-names>HS</given-names></name>
</person-group>. <article-title>Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations</article-title>. <source>Kidney Int</source>. <year>1985</year>;<volume>28</volume>(<issue>6</issue>): <fpage>951</fpage>–<lpage>958</lpage>.</citation>
</ref>
<ref id="bibr164-0884533612467824">
<label>164.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kokot</surname><given-names>F</given-names></name>
<name><surname>Pietrek</surname><given-names>J</given-names></name>
<name><surname>Srokowska</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>25-Hydroxyvitamin D in patients with essential hypertension</article-title>. <source>Clin Nephrol</source>. <year>1981</year>;<volume>16</volume>(<issue>4</issue>):<fpage>188</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr165-0884533612467824">
<label>165.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perry</surname><given-names>HM</given-names><suffix>III</suffix></name>
<name><surname>Jensen</surname><given-names>J</given-names></name>
<name><surname>Kaiser</surname><given-names>FE</given-names></name>
<name><surname>Horowitz</surname><given-names>M</given-names></name>
<name><surname>Perry</surname><given-names>HM</given-names><suffix>Jr</suffix></name>
<name><surname>Morley</surname><given-names>JE</given-names></name>
</person-group>. <article-title>The effects of thiazide diuretics on calcium metabolism in the aged</article-title>. <source>J Am Geriatr Soc</source>. <year>1993</year>;<volume>41</volume>(<issue>8</issue>):<fpage>818</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr166-0884533612467824">
<label>166.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Sinz</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>(<issue>2</issue>):<fpage>258</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr167-0884533612467824">
<label>167.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marechal</surname><given-names>JD</given-names></name>
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Brown</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer</article-title>. <source>Drug Metab Dispos</source>. <year>2006</year>;<volume>34</volume>(<issue>4</issue>): <fpage>534</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr168-0884533612467824">
<label>168.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loose</surname><given-names>DS</given-names></name>
<name><surname>Kan</surname><given-names>PB</given-names></name>
<name><surname>Hirst</surname><given-names>MA</given-names></name>
<name><surname>Marcus</surname><given-names>RA</given-names></name>
<name><surname>Feldman</surname><given-names>D</given-names></name>
</person-group>. <article-title>Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes</article-title>. <source>J Clin Invest</source>. <year>1983</year>;<volume>71</volume>(<issue>5</issue>):<fpage>1495</fpage>–<lpage>1499</lpage>.</citation>
</ref>
<ref id="bibr169-0884533612467824">
<label>169.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollis</surname><given-names>BW</given-names></name>
<name><surname>Horst</surname><given-names>RL</given-names></name>
</person-group>. <article-title>The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2007</year>;<volume>103</volume>(<issue>3–5</issue>):<fpage>473</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr170-0884533612467824">
<label>170.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binkley</surname><given-names>N</given-names></name>
<name><surname>Krueger</surname><given-names>D</given-names></name>
<name><surname>Cowgill</surname><given-names>CS</given-names></name>
<etal/></person-group>. <article-title>Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>7</issue>):<fpage>3152</fpage>–<lpage>3157</lpage>.</citation>
</ref>
<ref id="bibr171-0884533612467824">
<label>171.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carter</surname><given-names>GD</given-names></name>
<name><surname>Carter</surname><given-names>CR</given-names></name>
<name><surname>Gunter</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2004</year>;<volume>89–90</volume>(<issue>1–5</issue>):<fpage>467</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr172-0884533612467824">
<label>172.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tai</surname><given-names>SS</given-names></name>
<name><surname>Bedner</surname><given-names>M</given-names></name>
<name><surname>Phinney</surname><given-names>KW</given-names></name>
</person-group>. <article-title>Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography–tandem mass spectrometry</article-title>. <source>Anal Chem</source>. <year>2010</year>;<volume>82</volume>(<issue>5</issue>):<fpage>1942</fpage>–<lpage>1948</lpage>.</citation>
</ref>
<ref id="bibr173-0884533612467824">
<label>173.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rendic</surname><given-names>S</given-names></name>
</person-group>. <article-title>Summary of information on human CYP enzymes: human P450 metabolism data</article-title>. <source>Drug Metab Rev</source>. <year>2002</year>;<volume>34</volume>(<issue>1–2</issue>):<fpage>83</fpage>–<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr174-0884533612467824">
<label>174.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S</given-names></name>
<name><surname>Yung Chan</surname><given-names>S</given-names></name>
<name><surname>Cher Goh</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs</article-title>. <source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>304</lpage>.</citation>
</ref></ref-list>
</back>
</article>